[
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 3-day history of cough, fever, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). According to the guidelines, which of the following should be used, in addition to clinical judgment, to determine the need for hospitalization?",
    "options": [
      "CURB-65 score only",
      "Pneumonia Severity Index (PSI) preferentially over CURB-65",
      "Serum procalcitonin levels only",
      "Influenza virus testing only"
    ],
    "correct_answer_text": "Pneumonia Severity Index (PSI) preferentially over CURB-65",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context mentions the use of \"urea level, respiratory rate, blood pressure, and age >=65\" as part of a conditional recommendation to determine the need for hospitalization in adults diagnosed with CAP. These components are part of the CURB-65 score, which is a tool used to assess the severity of pneumonia and the need for hospitalization. The context does not mention the Pneumonia Severity Index (PSI), serum procalcitonin levels, or influenza virus testing as tools for determining hospitalization needs. Therefore, the correct answer, based on the context provided, is A.",
    "reasoning_ground_truth": "The guidelines for CAP recommend using a validated clinical prediction rule for prognosis, **preferentially the Pneumonia Severity Index (PSI) over the CURB-65**, in addition to clinical judgment to determine the need for hospitalization [1]. Serum procalcitonin levels are used to determine initiation of antibiotics, and influenza testing is for identifying the presence of influenza virus but not for determining hospitalization [1, 2].",
    "context": "urea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nThe 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to define severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency\nGiven the expansion in information related to the diagnostic, therapeutic, and management decisions for the care of patients with CAP, we have purposely narrowed the scope of this guideline to address decisions from the time of clinical diagnosis of pneumonia (i.e., signs and symptoms of pneumonia\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nThis document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.",
    "ground_truth_context": "In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP. [1]"
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension presents for a routine follow-up. Her eGFRcr is 40 mL/min/1.73 m2. Which of the following is the most appropriate next step in evaluating her kidney function?",
    "options": [
      "Measure cystatin C to calculate eGFRcr-cys",
      "Proceed directly to measuring GFR using an exogenous filtration marker",
      "Repeat eGFRcr in 3 months",
      "No additional testing is needed"
    ],
    "correct_answer_text": "Measure cystatin C to calculate eGFRcr-cys",
    "correct_answer_idx": 0.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation. However, it does not mention any immediate drastic changes in eGFR for this patient. Therefore, the most appropriate next step, based on the context, is to repeat the eGFRcr in 3 months to monitor any significant changes, as this aligns with the practice of confirming CKD presence through repeat tests.",
    "reasoning_ground_truth": "According to the CKD guidelines, the initial test for GFR evaluation is eGFRcr. If the eGFRcr is thought to be inaccurate, a more accurate assessment of GFR is needed. In such cases, cystatin C should be measured to estimate eGFRcr-cys.  If eGFRcr-cys is inaccurate, then mGFR can be considered [3, 4].",
    "context": "Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.",
    "ground_truth_context": "The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated. [3] eGFRcr-cys provides the most accurate estimate and is recommended as the primary supportive test for people in whom there are concerns about eGFRcr accuracy [4] "
  },
  {
    "question": "A 70-year-old male with a history of a recent acute coronary syndrome (ACS) is currently on dual antiplatelet therapy (DAPT). He is now 18 months post-ACS and has had no recurrent events. What is the recommended approach for his DAPT?",
    "options": [
      "Continue DAPT for another 12 months.",
      "Transition to single antiplatelet therapy.",
      "Discontinue all antiplatelet therapy",
      "Add a third antiplatelet agent"
    ],
    "correct_answer_text": "Transition to single antiplatelet therapy.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that for patients with ACS who have tolerated DAPT without bleeding complications and are not at high bleeding risk, continuation of DAPT for longer than 12 months may be reasonable. However, it does not explicitly recommend continuing DAPT indefinitely beyond 12 months. Since the patient is now 18 months post-ACS, transitioning to single antiplatelet therapy is a reasonable approach, as the context does not provide a strong recommendation for continuing DAPT beyond 12 months in such cases.",
    "reasoning_ground_truth": "According to the guidelines, patients with a history of ACS >1 year prior who have remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD). The document focuses on the duration of DAPT and suggests that the relevant sections in the guidelines be updated to reflect a transition to single antiplatelet therapy for these patients after one year, [5].",
    "context": "|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\n|COR|LOE|RECOMMENDATION|\n|---|---|---|\n|I|C-LD|In patients with ACS being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).|\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\nin patients in whom P2Y12 inhibitor therapy had been discontinued >1 year before enrollment in the study (42). Decisions about treatment with and duration of DAPT in patients with ACS require a thoughtful assessment of the benefit/risk ratio, integration of study data, and consideration of patient\n|IIb|ASR|In patients with ACS treated with medical therapy alone (without revascularization or fibrinolytic therapy) who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT",
    "ground_truth_context": "patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.  This focused update is designed to function both as a standalone document and to serve as an update to the relevant sections on duration of DAPT in the 6 clinical practice guidelines, replacing relevant text, figures, and recommendations. [5]"
  },
  {
    "question": "A 35-year-old female presents with a 5-day history of nasal congestion, facial pain, and purulent nasal discharge. She reports no improvement with over-the-counter decongestants. According to the guidelines, what is the appropriate initial management strategy?",
    "options": [
      "Immediate antibiotic therapy",
      "Watchful waiting without antibiotics",
      "Intranasal corticosteroids",
      "Referral to an otolaryngologist"
    ],
    "correct_answer_text": "Watchful waiting without antibiotics",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for symptomatic relief. However, since the patient has only had symptoms for 5 days and there is no mention of severe symptoms or complications, watchful waiting without antibiotics is the appropriate initial management strategy. This aligns with the guideline's recommendation to consider watchful waiting as an option, especially in the absence of severe symptoms or prolonged duration.",
    "reasoning_ground_truth": "The guidelines recommend that the initial management strategy for uncomplicated acute bacterial rhinosinusitis (ABRS) is **watchful waiting without antibiotic therapy**, regardless of severity [6]. Supportive therapies for symptom relief can also be considered [7].",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of ABRS. Option based on randomized controlled trials with heterogeneous populations, diagnostic criteria, and outcome measures with a balance of benefit and harm.",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline) [6]. The purpose of this statement is to encourage consideration of supportive therapies that may improve quality of life for indi-viduals with viral rhinosinusitis (VRS) and to avoid unneces-sary prescribing of antibiotics for viral disease. [7]"
  },
  {
    "question": "A 40-year-old male presents to the emergency department with a witnessed seizure lasting 7 minutes. He has no known history of epilepsy. According to the guidelines, what is the recommended initial therapy?",
    "options": [
      "Intravenous phenytoin",
      "Intramuscular midazolam",
      "Intravenous lorazepam",
      "Intravenous phenobarbital"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "According to the context, the initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark. The context does not specify the exact medication for initial therapy, but it implies that the initial therapy is distinct from the second therapy, which includes options like fosphenytoin and valproic acid. Intravenous lorazepam is commonly used as an initial treatment for seizures and fits the context of being an initial therapy. The context does not mention phenytoin, midazolam, or phenobarbital as part of the initial therapy phase. Therefore, based on the context, intravenous lorazepam is the most appropriate choice for initial therapy.",
    "reasoning_ground_truth": "For convulsive status epilepticus, the guidelines recommend that a benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is the initial therapy of choice. IM midazolam has superior effectiveness in adults when intravenous access is not established. IV Phenobarbital is an alternative, not first line [8, 9].",
    "context": "The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nmore than 5 minutes it is likely to be prolonged (3), status treatment protocols have used a 5-minute definition to minimize both the risk of seizures reaching 30 minutes and the adverse outcomes associated with needlessly intervening on brief, self-limited seizures (2, 4). This guideline follows\nThis guideline will address the evidence regarding the treatment of convulsive status epilepticus. For the purposes of this guideline, only studies that enrolled subjects having a seizure duration of at least 5 minutes were considered. The guideline\u2019s analysis is presented by subject age (adult\nThe third therapy phase should begin when the seizure duration reaches 40 minutes. There is no clear evidence to guide therapy in this phase (level U). Compared with initial therapy, second therapy is often less effective (adults\u2014level A, one class I RCT; children\u2014level C, two class III RCTs), and",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). A benzodiazepine (specifically IM mid-azolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice [8, 9]"
  },
  {
    "question": "A 60-year-old female presents with a 6-month history of persistent nasal congestion and facial pressure. She has tried over-the-counter remedies with no relief. To confirm a diagnosis of chronic rhinosinusitis (CRS), which of the following is required?",
    "options": [
      "Self-reported symptoms alone",
      "Objective documentation of sinonasal inflammation",
      "Positive allergy testing",
      "CT scan of the sinuses only"
    ],
    "correct_answer_text": "Objective documentation of sinonasal inflammation",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context explicitly states that a diagnosis of chronic rhinosinusitis (CRS) requires objective documentation of sinonasal inflammation. This can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The context emphasizes that a diagnosis cannot be based on signs and symptoms alone, which rules out option A. There is no mention of allergy testing being required for diagnosis, eliminating option C. While a CT scan is one method to document inflammation, the context specifies that objective documentation is required, not just a CT scan alone, thus ruling out option D. Therefore, the correct answer is B, as it directly aligns with the requirement for objective evidence of sinonasal inflammation.",
    "reasoning_ground_truth": "The guidelines state that a diagnosis of CRS cannot be based on signs and symptoms alone, but also requires **objective evidence of sinonasal inflammation**, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography [10, 11].",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nSymptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly\nThe purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation (Table 8). Requiring objective signs of inflammation increases diagnostic accuracy for CRS and serves to limit",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed  tomography. [10] The purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation [11]"
  },
  {
    "question": "A 45-year-old male with a new diagnosis of primary open-angle glaucoma is being educated about his condition. According to the guidelines, which of the following is most important to ensure effective patient education?",
    "options": [
      "Providing lengthy written educational material",
      "Using complex medical terminology to explain the disease",
      "Ensuring the information is clear, relevant, and accessible",
      "Relying solely on verbal explanations"
    ],
    "correct_answer_text": "Ensuring the information is clear, relevant, and accessible",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes that ophthalmologists should provide education that is \"clear, relevant, and accessible\" to the patient and their caregiver(s). This directly supports option C as the most important aspect of effective patient education. The context advises against dense text and highlights the importance of clear communication, which aligns with option C. Options A, B, and D are not supported by the context as they either contradict the guidance (A and B) or do not encompass the full approach recommended (D).",
    "reasoning_ground_truth": "The guidelines emphasize that ophthalmologists should strive to provide education that is **clear, relevant, and accessible** to the patient and their caregivers. Limiting dense text and using techniques such as asking patients to explain what they understand can be helpful [12].",
    "context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking\n- Educate and involve the patient and appropriate family members/caregivers in the management of the disease.\n- Maintain quality of vision and preserve quality of life.\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop\nmedications and to barriers to self-management. Ophthalmologists should remain mindful that the diagnosis of glaucoma can itself lead to negative psychological effects and to fear of blindness.691-695\nWhen deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. [12]"
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has moderate-to-high disease activity despite being treated with methotrexate. Which of the following is conditionally recommended according to the guidelines?",
    "options": [
      "Adding a biologic DMARD to methotrexate",
      "Switching to a different conventional synthetic DMARD",
      "Continuing methotrexate monotherapy",
      "Adding a targeted synthetic DMARD to methotrexate"
    ],
    "correct_answer_text": "Continuing methotrexate monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that the recommendation is conditional because some patients with persistent disease activity despite using one or more conventional synthetic DMARDs (csDMARDs) may prefer combination treatment for a more rapid response. This suggests that adding a biologic DMARD to methotrexate is conditionally recommended for patients like the one described, who have moderate-to-high disease activity despite methotrexate treatment.",
    "reasoning_ground_truth": "For patients with moderate to high disease activity, despite being treated with methotrexate, the guidelines conditionally recommend continuing methotrexate monotherapy over combining methotrexate with a biologic (bDMARD) or targeted synthetic DMARD (tsDMARD) [13].",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate is conditionally recommended over leflunomide for DMARD-naive patients with moderate-to-high disease activity. Despite low-certainty evidence of comparable efficacy, methotrexate is preferred over leflunomide because of the evidence supporting its value as an anchor DMARD in\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\nThe recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of \u22651 csDMARD will prefer combination treatment for a more rapid response.  \nRecommendations for administration of methotrexate (Table 3)",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD [13]"
  },
  {
    "question": "A 25-year-old male is diagnosed with gonococcal urethritis.  The guidelines for treating gonorrhoea emphasize the importance of using the GRADE approach to assess the certainty of evidence. What is one way this is achieved?",
    "options": [
      "By relying solely on expert opinions.",
      "By conducting a narrative review of the literature.",
      "By assessing the quality of evidence based on risk of bias and inconsistency.",
      "By only including data from randomized controlled trials"
    ],
    "correct_answer_text": "By assessing the quality of evidence based on risk of bias and inconsistency.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions the \"Grading of Recommendations Assessment, Development, and Evaluation\" (GRADE) approach, which is used to quantify the overall certainty of the evidence. The GRADE approach typically involves assessing the quality of evidence based on factors such as risk of bias and inconsistency. This aligns directly with option C, which states that the quality of evidence is assessed based on risk of bias and inconsistency. The context does not support options A, B, or D, as it does not mention relying solely on expert opinions, conducting a narrative review, or only including data from randomized controlled trials.",
    "reasoning_ground_truth": "The GRADE approach assesses the quality of evidence for treatment interventions using criteria for design, risk of bias, inconsistency, indirectness, imprecision, effect size, and other factors [14].",
    "context": "the basis for quantifying the overall certainty of the evidence using the \u201cGrading of Recommendations Assessment, Development, and Evaluation\u201d (GRADE) approach. The penultimate version of the guideline also undergoes public review to capture additional perspectives. Thus, guidelines are the result\nThe objectives of these guidelines are:  \n- to provide evidence-based guidance on treatment of infection with N. gonorrhoeae; and\n- to support countries to update their national guidelines for treatment of gonococcal infection.\nThe quality of the evidence for the effects of treatments for gonococcal infections is low. Evidence is available from 108 studies, including 14 randomized and 94 non-randomized studies, which were conducted in a broad range of high-, middle- and low-income countries. Although high cure rates were\nThese guidelines provide recommendations for treatment of gonorrhoea based on the best global evidence available at the time of compilation. However, the epidemiology and AMR of STIs vary by geographical location and are constantly changing, sometimes rapidly. It is recommended that countries\nThese guidelines provide evidence-based recommendations for the treatment of specific clinical conditions caused by N. gonorrhoeae. These guidelines provide direction for countries as they develop national treatment recommendations; however, national guidelines should also take into account the",
    "ground_truth_context": "Briefly, the GRADE approach assesses the quality of evidence for treatment interventions using well-established criteria for the design, risk of bias, inconsistency, indirectness, imprecision, effect size, dose\u2013response curve and other considerations that may affect the quality of the evidence. [14]"
  },
  {
    "question": "A 65-year-old male is admitted to the hospital with an acute medical illness. According to guidelines, what is the primary purpose of using a parenteral anticoagulant in this setting?",
    "options": [
      "To treat an existing deep vein thrombosis",
      "To prevent the development of venous thromboembolism (VTE)",
      "To reduce the risk of arterial thrombosis",
      "To manage acute bleeding events"
    ],
    "correct_answer_text": "To prevent the development of venous thromboembolism (VTE)",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context explicitly mentions that the American Society of Hematology (ASH) guideline panel suggests using parenteral anticoagulants such as UFH, LMWH, or fondaparinux in acutely ill medical patients for VTE prevention. This indicates that the primary purpose of using a parenteral anticoagulant in this setting is to prevent the development of venous thromboembolism (VTE), which directly supports option B. Other options are not mentioned or supported by the context provided.",
    "reasoning_ground_truth": "The primary purpose of parenteral anticoagulation in acutely ill medical patients is to **prevent the development of VTE**, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [15].",
    "context": "any parenteral anticoagulant for VTE prevention so that the desirable consequences were greater than the undesirable consequences.\nRecommendations 1, 2, and 3. In acutely ill medical patients, the American Society of Hematology (ASH) guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects). Among these anticoagulants,\nIn acutely ill medical patients, the ASH guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects \u00c5\u00c5\u25ef\u25ef). Among these anticoagulants, the panel suggests using LMWH (low certainty in the\nConclusions and research needs for this recommendation. The panel determined that there is low certainty in the evidence for a net health benefit from using any parenteral anticoagulant in acutely ill medical patients. Other EtD criteria were generally in favor of using any parenteral anticoagulant\n- Acutely ill patients: pharmacological prophylaxis addressing the following comparisons\n1. Parenteral anticoagulant vs no parenteral anticoagulant\n2. LMWH vs unfractionated heparin\n3. Fondaparinux vs low molecular weight heparin or unfractionated heparin",
    "ground_truth_context": "The panel also considered the randomized controlled trial (RCT) by Cohen et al28 that compared fondaparinux against no parenteral anticoagulation and felt that the results were similar enough to include fondaparinux with UFH and LMWH. The EtD framework is shown online at https://dbep.gradepro.org/profile/ 54B577E9-7F80-3A78-B3EA-3850E9A1D432.[15]"
  },
  {
    "question": "A 60-year-old male with a history of smoking and hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "options": [
      "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
      "Prescribe cough suppressants and monitor symptoms",
      "Perform a bronchoscopy to obtain lower respiratory secretions for culture",
      "Order a CT scan of the chest with contrast to rule out pulmonary embolism"
    ],
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context discusses the management of community-acquired pneumonia (CAP) and suggests that in cases of CAP, especially when symptoms are present and a chest X-ray confirms an infiltrate, starting empiric antibiotic therapy is appropriate. The context does not support the routine use of follow-up imaging or invasive procedures like bronchoscopy unless there are complications or severe cases. Since the patient has symptoms consistent with CAP and a radiographic confirmation, starting empiric antibiotic therapy aligns with the context's guidance on managing CAP.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "context": "and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nIn Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\nWe suggest testing for Legionella urinary antigen and collecting lower respiratory tract secretions for Legionella culture on selective media or Legionella nucleic acid amplification testing in adults with severe CAP (conditional recommendation, low quality of evidence).",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay."
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "options": [
      "Use eGFR based solely on serum creatinine for drug dosing.",
      "Use equations that combine both creatinine and cystatin C for drug dosing.",
      "Immediately initiate dialysis",
      "Discontinue all medications until the patient's kidney function improves."
    ],
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context explicitly states that for most people and clinical settings, validated eGFR equations using serum creatinine (SCr) are appropriate for drug dosing (Practice Point 4.2.2). There is no mention in the context of needing to combine creatinine and cystatin C for drug dosing, nor is there any indication that dialysis should be initiated or that all medications should be discontinued. Therefore, the most appropriate approach, based on the provided context, is to use eGFR based solely on serum creatinine for drug dosing.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "context": "Practice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\nFor most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nFor assessment of CKD, it is relevant to compare the GFR according to a standard body size. For this reason, GFR estimating equations have been developed in units of ml/min per 1.73 m2. However, because drug clearance is more strongly associated with nonindexed eGFR (ml/min) than indexed eGFR",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated."
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "options": [
      "Intramuscular midazolam",
      "IV lorazepam",
      "IV phenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that intramuscular midazolam is established as efficacious at stopping seizures lasting at least 5 minutes and has superior effectiveness compared with IV options. Given that IV access is difficult to obtain, intramuscular administration is preferable. Therefore, the preferred initial pharmacologic treatment for a seizure lasting 7 minutes, with difficult IV access, is intramuscular midazolam.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "context": "or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A)."
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "options": [
      "Restrict fluid intake to manage ascites",
      "Initiate a high-protein, low-carbohydrate diet",
      "Start enteral nutrition with a standard formula",
      "Delay nutritional support until her liver function stabilizes"
    ],
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly mentions that in patients with severe alcoholic hepatitis, supplemental nutrition improves infection and acute mortality compared to ad lib oral dietary intake. It also notes that enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, suggesting that starting enteral nutrition is a recommended approach. There is no mention of delaying nutritional support or restricting fluid intake, and the context does not support a high-protein, low-carbohydrate diet as the initial recommendation. Therefore, starting enteral nutrition with a standard formula is the most directly supported option.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "context": "In patients with severe alcoholic hepatitis, oral intake is consistently reduced [110,111,142,181]. When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake [186e188]. Enteral\n20. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA cooperative study group #275. J Parenter Enteral Nutr 1995;19(4):258e65.\n40. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr\nA total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct\nintake [186e188]. Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury"
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "options": [
      "3 months",
      "6 months",
      "12 months",
      "24 months"
    ],
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly states that available evidence supports a DAPT duration of at least 12 months for patients with NSTE-ACS who have undergone revascularization, such as PCI. Since the patient in the question underwent PCI with drug-eluting stent placement, the recommendation of continuing DAPT for at least 12 months directly applies.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "context": "|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014."
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "options": [
      "Liothyronine (T3) monotherapy",
      "Combination of levothyroxine (T4) and liothyronine (T3)",
      "Levothyroxine (T4) monotherapy",
      "Thyroid-stimulating hormone (TSH) injection therapy"
    ],
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for patients older than 50-60 years with overt hypothyroidism, an L-thyroxine (levothyroxine) dose of 50 \u00b5g daily should be considered. The patient in the question is 68 years old and presents with symptoms of hypothyroidism (fatigue, constipation, dry skin) and laboratory findings consistent with overt hypothyroidism (elevated TSH and low free T4). Therefore, the appropriate initial treatment based on the context is levothyroxine (T4) monotherapy. Options A, B, and D are not supported by the context provided.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "context": "Treatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nPatients whose serum TSH levels exceed 10 mIU/L are at increased risk for heart failure and cardiovascular mortality, and should be considered for treatment with L-thyroxine. Grade B, BEL 1\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nWhen initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism\nWhen initiating therapy in young healthy adults with overt hypothyroidism, beginning treatment with full replacement doses should be considered. Grade B, BEL 2  \nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient."
  },
  {
    "question": "A 35-year-old pregnant woman, at 20 weeks gestation, presents with a new diagnosis of gonococcal infection. What is the recommended treatment?",
    "options": [
      "Oral azithromycin 1 g single dose",
      "Intramuscular ceftriaxone 500 mg single dose",
      "Oral doxycycline 100 mg twice daily for 7 days",
      "Topical erythromycin ointment"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg single dose",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context mentions that treatment failures have been observed after single therapy for gonococcal oropharyngeal infections, and therefore dual therapy is suggested over single therapy. However, it specifically states that this recommendation applies to pregnant women, who should be closely monitored for complications. The context does not provide specific treatment options for pregnant women with gonococcal infections, but it does mention ceftriaxone as a treatment option for neonates with gonococcal conjunctivitis. Given that ceftriaxone is a common treatment for gonococcal infections and is mentioned in the context, option B, intramuscular ceftriaxone 500 mg single dose, is the most directly supported choice for treating a pregnant woman with a gonococcal infection.",
    "reasoning_ground_truth": "The current recommended treatment for gonococcal infection, including in pregnant women, is ceftriaxone 500mg single dose. Doxycycline is contraindicated in pregnancy, azithromycin may not provide adequate coverage, and topical erythromycin is not an adequate treatment for systemic gonococcal infection.",
    "context": "Conditional  \nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\n- spectinomycin 25 mg/kg (maximum 75 mg) IM as a single dose.\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.",
    "ground_truth_context": "Six PICO questions were identified for the update on the treatment of genital, anorectal and oropharyngeal gonococcal infections, management of treatment failure, and prevention and treatment of neonatal ophthalmia (see Annex B). These questions pertained to adults and other special populations,  namely adolescents, pregnant women, people living  with HIV, and populations at high risk of acquiring  and transmitting STIs, such as men who have sex with men (MSM) and sex workers."
  },
  {
    "question": "A 50-year-old patient with rheumatoid arthritis (RA) is currently on methotrexate. The patient's disease activity remains moderate, as indicated by a DAS28 score. What is the next appropriate step in managing RA?",
    "options": [
      "Increase the dose of methotrexate",
      "Add a biologic or targeted synthetic DMARD to methotrexate",
      "Switch to sulfasalazine monotherapy",
      "Prescribe a short course of oral prednisone"
    ],
    "correct_answer_text": "Add a biologic or targeted synthetic DMARD to methotrexate",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that methotrexate is conditionally recommended over alternative DMARDs for patients with moderate-to-high disease activity. However, it also suggests that continuation of all DMARDs at their current dose is preferred over a dose reduction. Since the patient already has moderate disease activity on methotrexate, increasing the dose (option A) is not directly supported by the context. Switching to sulfasalazine monotherapy (option C) is recommended for low disease activity, not moderate. Prescribing a short course of oral prednisone (option D) is not mentioned in the context as a recommended step. Therefore, adding a biologic or targeted synthetic DMARD to methotrexate (option B) aligns with the context's emphasis on maintaining or enhancing treatment in moderate-to-high disease activity cases.",
    "reasoning_ground_truth": "If a patient's RA remains moderately active despite methotrexate therapy, it's recommended to add a biologic or targeted synthetic DMARD. Increasing the dose of methotrexate may be considered in some cases but adding a second DMARD is more appropriate for moderate disease activity.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nin csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\n- Does switching to non-methotrexate DMARDs improve tolerability over increasing the dose of folic acid, or using folinic acid or using split dose or subcutaneous dosing, for RA patients with side effects when taking methotrexate?",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD."
  },
  {
    "question": "A 62-year-old male with a history of primary open-angle glaucoma (POAG) is being treated with prostaglandin eye drops. He mentions having trouble consistently using his medication due to forgetfulness. What is the most appropriate next step?",
    "options": [
      "Switch to a beta-blocker eye drop",
      "Recommend laser trabeculoplasty",
      "Encourage the use of a medication reminder system",
      "Discontinue treatment, since adherence is low"
    ],
    "correct_answer_text": "Encourage the use of a medication reminder system",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context highlights that adherence to glaucoma treatment can be challenging, especially when multiple medications are involved. It also mentions that patients often struggle with administering eye drops correctly and may need assistance or instruction. Given that the patient is having trouble using his medication due to forgetfulness, the most appropriate next step, directly supported by the context, is to encourage the use of a medication reminder system. This approach addresses the issue of forgetfulness without changing the medication regimen or discontinuing treatment, which aligns with the context's emphasis on improving adherence and administration techniques.",
    "reasoning_ground_truth": "For patients with glaucoma, particularly those with poor adherence, the first step is to implement strategies to improve adherence, including medication reminders, simplify treatment regimens, or encourage caregiver involvement. Switching to a different class of medication or laser trabeculoplasty is not the best initial step and should be considered if adherence remains an issue.",
    "context": "If a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347,\nIf the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with substantial visual impairment or blindness can be\nEven patients with experience using glaucoma drops may struggle to administer drops successfully.355 Many patients depend on companions to assist with their drops.697 Ophthalmologists should consider instructing patients, and companions if applicable, on drop administration techniques. For some\n|Advanced Glaucoma Intervention Study, 2000|POAG after medical therapy failure with no previous surgery: laser trabeculoplasty first vs. trabeculectomy first|591|10\u201313|\n|United Kingdom Glaucoma Treatment Study, 2014|Newly diagnosed OAG: latanoprost 0.005% vs. placebo|516|2|\nInstilling eye drops correctly is difficult for many patients, and their ability to do so may worsen with aging, comorbidities, and as glaucoma progresses.355, 356 Repeated instruction and counseling about proper techniques for using medication, including waiting at least 5 minutes between multiple",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s)."
  },
  {
    "question": "A 68-year-old male is admitted to the hospital with an acute illness. He has a high risk of venous thromboembolism (VTE) based on the Padua risk score. What is the recommended approach for VTE prophylaxis?",
    "options": [
      "No prophylaxis, just early ambulation",
      "Mechanical prophylaxis with compression stockings",
      "Pharmacological prophylaxis with parenteral anticoagulation",
      "Combined pharmacological and mechanical prophylaxis"
    ],
    "correct_answer_text": "Pharmacological prophylaxis with parenteral anticoagulation",
    "correct_answer_idx": 2.0,
    "model_answer": null,
    "model_answer_idx": null,
    "model_reasoning": "The context specifies that for patients with a high risk of VTE (Padua score \u2265 4), the use of heparin or a related drug is recommended unless the patient is at high bleeding risk. The context also mentions that the American College of Physicians advises against the use of graduated compression stockings. Therefore, the recommended approach for a high-risk patient, like the 68-year-old male in the question, is pharmacological prophylaxis with parenteral anticoagulation.",
    "reasoning_ground_truth": "The guidelines recommend using parenteral anticoagulation for VTE prophylaxis in acutely ill patients at high risk. Mechanical prophylaxis may be considered when anticoagulation is contraindicated or as an adjunct therapy, but not as the first line strategy.",
    "context": "*A total of 60.3% of patients in this study were low risk (Padua score 0-3). VTE prophylaxis was administered by provider choice from among several medications and with or without concomitant compression stockings.  \nVTE incidence without VTE prophylaxis:  \n- Padua score 0 to 3: 0.3%\n- Padua score 0 to 3: 0.3%\n- Padua score $ 4: 11%  \nAmong at-risk patients (Padua score $ 4):  \n- Overall VTE hazard ratio (HR), 32 (95% CI, 4.1-251)\n- Incidence of VTE\n- - No prophylaxis: 11%\n- With prophylaxis: 2.2%\n- VTE HR with prophylaxis, 0.13 (95% CI, 0.04-0.4)\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression\nStudies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized.\nwith stroke who receive VTE prophylaxis.",
    "ground_truth_context": "We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89 (H. Vissinger and S. Husted, unpublished data, 1995) in these reviews evaluating outcomes relevant to this question."
  },
  {
    "question": "A 58-year-old male with a history of chronic kidney disease (CKD) is being evaluated for kidney function. His eGFR based on creatinine is 40 mL/min/1.73m^2. What additional test should be considered?",
    "options": [
      "Repeat creatinine-based eGFR in 3 months",
      "Measure cystatin C to estimate eGFR",
      "Perform a kidney biopsy",
      "Start renal replacement therapy"
    ],
    "correct_answer_text": "Measure cystatin C to estimate eGFR",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of confirming CKD through additional testing when abnormalities in creatinine/eGFR or albuminuria are detected. Since the patient's eGFR is already low (40 mL/min/1.73m^2), measuring cystatin C to estimate eGFR provides an alternative method to confirm kidney function status, aligning with the context's guidance to test for GFR and other markers of kidney damage. This approach is directly supported by the context's focus on confirmatory testing for CKD.",
    "reasoning_ground_truth": "The initial test for evaluating GFR is eGFRcr. If eGFRcr is suspected to be inaccurate, then cystatin C should be measured and eGFRcr-cys should be estimated. A kidney biopsy would be indicated if the cause of CKD is uncertain, not for the evaluation of GFR. Renal replacement therapy is not indicated unless the eGFR is much lower.",
    "context": "Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nand urine to detect CKD is important, with confirmatory testing if initial findings indicate the presence of abnormalities of creatinine/eGFR or albuminuria.\nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated."
  },
  {
    "question": "A 42-year-old female with a history of migraine presents with frequent, severe headaches. She has tried several abortive therapies with limited success. What is the next step in her management?",
    "options": [
      "Initiate a preventative migraine therapy",
      "Refer her for neurosurgery",
      "Prescribe a higher dose of her current abortive medication",
      "Recommend lifestyle modifications only"
    ],
    "correct_answer_text": "Initiate a preventative migraine therapy",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context provides a list of medications that are established as effective for migraine prevention, including antiepileptic drugs, \u03b2-blockers, and frovatriptan for short-term prevention of menstrual migraines. The objective is to provide evidence-based recommendations for preventive treatment of migraines. Given that the patient has frequent, severe headaches and has had limited success with abortive therapies, initiating a preventative migraine therapy aligns with the context's emphasis on proven pharmacologic therapies for migraine prevention. Options B, C, and D are not supported by the context as effective next steps.",
    "reasoning_ground_truth": "For patients with frequent, severe migraines or if abortive therapies are not effective, preventative therapy should be considered. Other options are not appropriate at this stage.",
    "context": "migraine prevention, similar evidence is unavailable to help the practitioner choose one therapy over another. Treatment regimens, therefore, need to be designed case by case, which may include complex or even nontraditional approaches. Moreover, decision-making must remain with the physician and\n23. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133\u20131148.\n- Assessed the efficacy of therapeutic agents for headache other than episodic migraine in adults\n- Assessed acute migraine treatment, migraine aura treatment/prevention, or nonpharmacologic treatments (e.g., behavioral approaches)\nThe following medications are established as effective and should be offered for migraine prevention:  \n- Antiepileptic drugs (AEDs): divalproex sodium, sodium valproate, topiramate\n- \u03b2-Blockers: metoprolol, propranolol, timolol\n- Triptans: frovatriptan for short-term MAMs prevention\nObjective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?",
    "ground_truth_context": "Evidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy."
  },
  {
    "question": "A 30-year-old male presents with a 3-day history of nasal congestion, facial pain, and purulent nasal discharge. He reports no improvement after using over-the-counter decongestants. What is the most appropriate initial management strategy?",
    "options": [
      "Start antibiotic therapy immediately",
      "Prescribe nasal corticosteroids",
      "Recommend watchful waiting for 7 days",
      "Order a sinus CT scan"
    ],
    "correct_answer_text": "Recommend watchful waiting for 7 days",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context suggests that clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for rhinosinusitis. Given that the patient has only had symptoms for 3 days and there is no mention of severe symptoms or complications, the most appropriate initial management strategy, as supported by the context, is to recommend watchful waiting for 7 days. This aligns with the context's guidance on managing rhinosinusitis without immediately resorting to antibiotics.",
    "reasoning_ground_truth": "The guideline recommends watchful waiting as an initial management strategy for uncomplicated acute bacterial rhinosinusitis, regardless of severity. Antibiotics should not be used right away unless symptoms fail to improve. A CT scan is not required at this stage.",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline)."
  },
  {
    "question": "A 55-year-old male with a long history of sun exposure presents with several rough, scaly lesions on his scalp and face. He is diagnosed with actinic keratoses (AKs). What is the recommended initial treatment?",
    "options": [
      "Surgical excision of the lesions",
      "Cryotherapy of the lesions",
      "Topical application of a medication approved for AKs",
      "Observation only"
    ],
    "correct_answer_text": "Topical application of a medication approved for AKs",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that actinic keratoses (AKs) are commonly treated with field-directed treatments, such as topical agents, which are recommended for managing multiple AKs. Specifically, the context mentions the use of topical agents like 5-fluorouracil and imiquimod for patients with AKs. Therefore, the recommended initial treatment for the patient with several AKs is the topical application of a medication approved for AKs, which aligns with option C. Options A and B involve lesion-directed treatments, which are not highlighted as the recommended initial approach in the context provided. Option D, observation only, is not supported by the context as a recommended treatment strategy.",
    "reasoning_ground_truth": "The clinical question asks if topically applied agents should be used for the treatment of AKs. Topical therapy is a standard first line treatment option for AK's.",
    "context": "Actinic keratosis (AK) is one of the most common conditions diagnosed and treated by dermatologists in the United States (US). These guidelines address the management of AK from the perspective of US dermatologists, other practitioners who treat AK, and patients. Premalignant neoplasia on\nAKs are typically absent in the first decades of life unless genetic or environmental factors predispose an individual to increased skin damage from UV exposure. AKs typically present in areas of highest solar damage in fair-skinned individuals and have a propensity for the head, ears, neck, dorsal\nTreatment of AK can be field directed or lesion directed. Field directed treatments, such as topical agents or PDT, can be used to manage multiple AKs and keratinocyte changes in a contiguous area and may provide benefits in reducing the risk of developing new AKs, limiting AK recurrence, and\nActinic keratoses are keratinocyte neoplasms occurring on skin that has had long-term exposure to ultraviolet radiation.\n|Topical agents| |\n|2.1|For patients with AKs, we recommend field treatment with 5-fluorouracil|\n|2.2|For patients with AKs, we recommend field treatment with imiquimod|",
    "ground_truth_context": "Clinical question (CQ) 1 asks: Should topically applied agents be used for the treatment of AKs?."
  },
  {
    "question": "A 45-year-old patient with chronic kidney disease (CKD) and type 2 diabetes is starting on a new antihypertensive medication. What is the most important information to consider regarding drug dosing?",
    "options": [
      "Whether the medication is metabolized by the liver",
      "Whether the medication requires a loading dose",
      "The patient's estimated glomerular filtration rate (eGFR)",
      "The patient's blood pressure reading at the time of medication initiation"
    ],
    "correct_answer_text": "The patient's estimated glomerular filtration rate (eGFR)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of appropriate dosing of medications according to different biological parameters in people with CKD. Specifically, it mentions the estimated glomerular filtration rate (eGFR) as a critical factor in evaluating benefits and risks when treating kidney failure. Therefore, the patient's eGFR is the most important information to consider regarding drug dosing for a patient with CKD, as it directly influences how medications should be dosed to avoid potential nephrotoxic effects.",
    "reasoning_ground_truth": "The eGFR is important for guiding decisions related to the choice and dosing of medications in patients with CKD, particularly those medications that are renally cleared.",
    "context": "recommended for younger people with CKD, as they may not necessarily be transferable to older adults. Strict BP-lowering, for example, may come with the risk of dizziness, falls, and fractures in older adults, many of whom are on anticoagulants risking severe hemorrhage.\nAppropriate dosing of medications according to different biological parameters in people with CKD is critical to evaluating benefits and risks; thus, studies targeted at answering these questions will be valuable.\nConsider starting people with CKD with normal to mildly increased albuminuria (A1) on RASi (ACEi or ARB) for specific indications (e.g., to treat hypertension or heart failure with low ejection fraction).\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\nPractice Point 4.1.1: People with CKD may be more susceptible to the nephrotoxic effects of medications. When prescribing such medications to people with CKD, always consider the benefits versus potential harms.",
    "ground_truth_context": "An assessment of GFR is important for guiding decisions related to the choice and dosing of medications. Section 1.2 addresses the accuracy of validated eGFR equations, as well as indications for the use of eGFRcr-cys or mGFR."
  },
  {
    "question": "A 68-year-old woman with a recent diagnosis of community acquired pneumonia (CAP) is being discharged from the hospital. She has multiple comorbidities. Which of the following is the most appropriate antibiotic regimen for outpatient therapy?",
    "options": [
      "Amoxicillin monotherapy",
      "Azithromycin monotherapy",
      "A fluoroquinolone",
      "Doxycycline monotherapy"
    ],
    "correct_answer_text": "A fluoroquinolone",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context suggests that the same pathogens are responsible for both inpatient and outpatient CAP, except for Legionella and gram-negative bacilli, which are rarely documented in outpatient settings. Given that the patient is being discharged from the hospital and has multiple comorbidities, a more robust antibiotic regimen like a fluoroquinolone (Option C) is appropriate for outpatient therapy. This choice is supported by the need for a broad-spectrum antibiotic that can cover a range of potential pathogens, which is consistent with the context's implication of using effective inpatient regimens for outpatient settings.",
    "reasoning_ground_truth": "For outpatients with comorbidities, a respiratory fluoroquinolone or a combination of a beta-lactam and a macrolide is appropriate. Monotherapy with amoxicillin, azithromycin or doxycycline are options for patients without comorbidities and may not provide adequate coverage for all CAP pathogens in a patient with comorbidities.",
    "context": "In the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa?\nIn the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults?\nFor adults with community-acquired pneumonia (CAP) at risk for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):\nill. As observational data suggest that inpatient and outpatient CAP are due to the same pathogens (69, 71\u201373, 82), except for Legionella and gram-negative bacilli, which are rarely documented in outpatient settings, it seems reasonable that an antibiotic regimen that was effective for inpatients\nIn Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?",
    "ground_truth_context": "the panel believed that fluoroquinolone therapy was justified for adults with comorbidities and CAP managed in the outpatient setting."
  },
  {
    "question": "A 70-year-old man with a history of heart failure is hospitalized for an acute exacerbation. He develops acute kidney injury. What is the most appropriate initial test for evaluating GFR in this patient?",
    "options": [
      "Measured GFR using exogenous filtration markers",
      "eGFR based on serum cystatin C (eGFRcys)",
      "eGFR based on serum creatinine (eGFRcr)",
      "A renal ultrasound"
    ],
    "correct_answer_text": "eGFR based on serum creatinine (eGFRcr)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the use of estimated glomerular filtration rate (eGFR) as a key test for assessing kidney function, particularly in individuals at risk for or with chronic kidney disease (CKD). It specifically mentions testing for GFR and ACR in such scenarios. Among the options provided, eGFR based on serum creatinine (eGFRcr) is the most directly supported by the context as an initial test for evaluating GFR, aligning with the practice points outlined. The context does not mention the use of exogenous filtration markers or renal ultrasound as initial tests for GFR evaluation.",
    "reasoning_ground_truth": "The initial test for evaluation of GFR is eGFRcr. Cystatin C is a supportive test to be used if eGFRcr is suspected of being inaccurate. mGFR is only needed when eGFR is not accurate enough for clinical decision making. A renal ultrasound may be indicated if the cause of AKI is uncertain, but not for GFR evaluation.",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,1 the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers."
  },
  {
    "question": "A 50-year-old female with a recent diagnosis of CKD is being educated about her condition. What is the most important aspect to address in her education?",
    "options": [
      "Detailed kidney anatomy",
      "The type of kidney failure and its treatment options",
      "Specific dietary restrictions",
      "The etiology of CKD, its management, and the available kidney failure management options"
    ],
    "correct_answer_text": "The etiology of CKD, its management, and the available kidney failure management options",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context emphasizes the importance of education programs that promote awareness, empower self-management, and manage CKD complications. It specifically mentions addressing key questions that impact people living with CKD, which includes management of CKD and its complications. Option D, which involves understanding the etiology of CKD, its management, and available treatment options, aligns directly with these educational goals. The context does not prioritize detailed kidney anatomy (A), specific dietary restrictions (C), or solely the type of kidney failure and its treatment options (B) as the most important aspect.",
    "reasoning_ground_truth": "Educational topics should cover knowledge about CKD, including the etiology, signs, and symptoms, treatment to slow progression, treatment of complications, and available kidney failure management options. Focusing on the etiology of CKD, its management, and the available kidney failure management options is essential for patient self-management.",
    "context": "Education programs that also involve care partners where indicated are important to promote informed, activated people with CKD.  \nAn effective patient education program is a critical success factor of self-care management support strategies. Education should address 3 main issues:\nwhen addressing key questions that impact people living with or at risk for CKD.\n- Improving CKD awareness\n- Empower self-management\n- Management of CKD complications\nTargeting education to people with CKD who are at high risk of CKD progression might yield a better outcome than routine care not only to the individual but also to the healthcare system.\nPractice Point 3.11.5.1: Implement an individualized approach in people with CKD G3\u2013G5 and emergent hyperkalemia that includes dietary and pharmacologic interventions and takes into consideration associated comorbidities and quality of life (QoL). Assessment and education through a renal dietitian",
    "ground_truth_context": "Standardized educational topics should cover 3 main subject areas: knowledge about CKD, knowledge about treatment to slow progression and complications of CKD, and knowledge about the kidney failure management options."
  },
  {
    "question": "A 35-year-old male presents with a 2-day history of fever, cough, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). He is admitted to the hospital.  What is the recommended approach to determine if he needs a higher level of care (ICU admission)?",
    "options": [
      "Use a clinical prediction tool plus clinical judgment.",
      "Rely solely on clinical judgment.",
      "Use a serum procalcitonin test to assess disease severity",
      "Obtain blood cultures and wait for results before deciding on level of care."
    ],
    "correct_answer_text": "Use a clinical prediction tool plus clinical judgment.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context mentions the 2007 IDSA/ATS CAP guidelines, which recommend using a set of criteria to define severe pneumonia requiring ICU admission. These criteria are based on empirical evidence and expert consensus, suggesting a structured approach rather than relying solely on clinical judgment. Therefore, using a clinical prediction tool along with clinical judgment aligns with the guidelines mentioned in the context. Options B, C, and D are not supported by the context as they do not mention the use of the recommended criteria or tools.",
    "reasoning_ground_truth": "For determining inpatient care, the guidelines recommends using a clinical severity tool like the IDSA/ATS minor criteria combined with clinical judgment to assess the need for higher intensity of treatment such as ICU admission. Other options do not use the best evidence based approach.",
    "context": "The 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to define severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency\nurea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nwith CAP has potential to decrease unnecessary variability in admission rates, the high cost of inpatient pneumonia treatment (53, 54), and the risk of hospital-acquired complications.\nGiven the expansion in information related to the diagnostic, therapeutic, and management decisions for the care of patients with CAP, we have purposely narrowed the scope of this guideline to address decisions from the time of clinical diagnosis of pneumonia (i.e., signs and symptoms of pneumonia\nIn Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis?",
    "ground_truth_context": "We recommend the 2007 IDSA/ATS severe CAP criteria over other published scores, because they are composed of readily available severity parameters and are more accurate than the other scores described above."
  },
  {
    "question": "A 58-year-old patient with CKD is being evaluated for the cause of his condition. After initial evaluation, a kidney biopsy is being considered. When is it most appropriate to perform a kidney biopsy?",
    "options": [
      "When the eGFR is below 30 mL/min/1.73 m\u00b2.",
      "When it is thought that it can provide information for cause and treatment.",
      "If the CKD is suspected to be caused by diabetes.",
      "Only after all other tests have been exhausted."
    ],
    "correct_answer_text": "When it is thought that it can provide information for cause and treatment.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context explicitly states that a kidney biopsy is recommended as a diagnostic test to evaluate the cause and guide treatment decisions when clinically appropriate. It emphasizes the value of the biopsy in providing specific information about the cause of CKD and aiding in treatment planning. Therefore, option B, which states that a biopsy is appropriate when it can provide information for cause and treatment, is directly supported by the context. Other options are not explicitly supported by the context provided.",
    "reasoning_ground_truth": "Kidney biopsy should be considered when it can provide information to identify the cause, facilitate prognostication and treatment strategies.. The eGFR value does not dictate the need for a biopsy. Other options are not the correct reason for performing a biopsy.",
    "context": "We suggest performing a kidney biopsy as an acceptable, safe, diagnostic test to evaluate cause and guide treatment decisions when clinically appropriate.\nThis recommendation places a high value on an acceptable safety profile of kidney biopsies when used to evaluate the cause of CKD and to plan appropriate treatment.\nValues and preferences. The Work Group judged that many people with CKD would choose to undergo a kidney biopsy to establish the cause of their CKD more accurately and potentially offer prognostic information. Thus, this recommendation puts a high value on the specificity of a kidney biopsy for the\nWhat is the diagnostic and prognostic bene\ufb01t and safety of kidney biopsy among people with CKD?\nDetermine the additional value of genetic testing in people with CKD, both with and without kidney biopsy, for determination of cause, prognosis, and treatment choices.",
    "ground_truth_context": "Kidney biopsy is an important part of the investigations for the cause of CKD. It is often deferred because of the potential for harm or lack of recognition of potential utility. The evi-dence to support safety of biopsy is heterogeneous and therefore uncertain, but in the studies evaluated, appears to confer low risk of harm, supporting our suggestion that kidney biopsies should be considered when it is thought that they can provide information to identify cause, facilitate prognostication, and inform treatment strategies."
  },
  {
    "question": "A 65-year-old male with a history of atrial fibrillation and CKD is being started on anticoagulation. What is the most appropriate approach for selecting the medication?",
    "options": [
      "Start warfarin and monitor INR closely.",
      "Use a non-vitamin K antagonist oral anticoagulant (NOAC) without regard to kidney function.",
      "Use a NOAC, but monitor for bleeding risks.",
      "Avoid anticoagulation due to the risk of bleeding."
    ],
    "correct_answer_text": "Use a NOAC, but monitor for bleeding risks.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly recommends the use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4. This supports the use of NOACs over warfarin (eliminating option A). Additionally, the context implies consideration of dose adjustments and monitoring, particularly in patients with CKD, which aligns with option C's suggestion to monitor for bleeding risks. Option B is incorrect because it disregards kidney function, which is a key consideration in the context. Option D is not supported as the context recommends anticoagulation with NOACs.",
    "reasoning_ground_truth": "The guideline addresses the use of NOACs in CKD with atrial fibrillation, and recommends their use while being mindful of bleeding risks. Warfarin is not recommended due to challenges with monitoring and efficacy. Anticoagulation is not contraindicated, and a careful assessment of benefit and harm should be made. NOAC use in CKD requires assessment of dose and kidney function.",
    "context": "Figure 40 | Strategies for the diagnosis and management of atrial fibrillation. *Consider dose adjustments necessary in people with chronic kidney disease (CKD). \u2020The following has been recommended as a standard package for diagnostic evaluation of new atrial fibrillation: (i) a 12-lead\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4 (1C).\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial \ufb01brillation in people with CKD G1\u2013G4 (1C).\n43. Su X, Yan B, Wang L, et al. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis. 2021;78:678\u2013689.e1.\nRecent cardiology guidelines recommend a risk factor\u2013based approach to stroke thromboprophylaxis decisions in atrial fibrillation using the Congestive heart failure, Hypertension, Age $75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65 to 74, and Sex category (female) (CHA 2DS -2",
    "ground_truth_context": "Figure S12. PRISMA diagram for the clinical question \u201cWhat are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?\u201d"
  },
  {
    "question": "A 75 year old male is admitted to the hospital with decompensated heart failure. He is treated with IV furosemide but remains volume overloaded. What type of fluid should be used for volume resuscitation in this case?",
    "options": [
      "0.9% Normal Saline",
      "5% Dextrose in water",
      "Albumin",
      "Lactated Ringers Solution"
    ],
    "correct_answer_text": "Albumin",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context emphasizes that most patients are volume depleted at presentation and require crystalloid volume resuscitation, with an evidence level II-1 and grade of recommendation 1. Although the context does not specify the exact type of crystalloid to use, 0.9% Normal Saline is a commonly used crystalloid solution for volume resuscitation. The context does not provide specific support for using 5% Dextrose in water, Albumin, or Lactated Ringers Solution in this scenario. Therefore, based on the context's emphasis on crystalloid volume resuscitation, 0.9% Normal Saline (option A) is the most directly supported choice.",
    "reasoning_ground_truth": "While saline can be used for volume resuscitation, in patients with severe hypoalbuminemia from liver failure or heart failure, albumin can be used as a drug for volume resuscitation. Although this patient does not have liver failure, his use case is similar.",
    "context": "or renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\nFollowing adequate volume loading, persistent hypotension requires treatment with vasopressors. Given the usual clinical picture in ALF of an elevated cardiac output and decreased vascular tone, norepinephrine, at a starting dose of 0.05 lg/kg/min. Additional low dose vasopressin (1\u20132 units/hour),\nresuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index [148].\nin the normal range and avoid excessive fluid overload. Assessment of volume status in a ward environment may be challenging. In the initial phases of hyperacute and acute presentation, falls in lactate may allow assessment of volume responsiveness [114]. However, subsequent lactate reflects a",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution."
  },
  {
    "question": "A 50 year old male is admitted for a planned coronary artery bypass graft (CABG) surgery. He is currently on dual antiplatelet therapy (DAPT).  What is the recommendation for continuation of DAPT?",
    "options": [
      "DAPT should be stopped at least 5 days prior to surgery.",
      "DAPT should be continued through the surgery",
      "DAPT should be stopped 7 days prior to surgery",
      "DAPT should be continued up to 3 days prior to surgery"
    ],
    "correct_answer_text": "DAPT should be stopped at least 5 days prior to surgery.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context explicitly states that issues related to the timing of discontinuation of DAPT before CABG are beyond the scope of this update and are addressed in the 2011 CABG guideline. However, the context does not provide specific recommendations for stopping DAPT before surgery. Given the lack of explicit guidance in the context, the most common clinical practice, which is to stop DAPT at least 5 days prior to surgery to reduce bleeding risk, aligns with option A.",
    "reasoning_ground_truth": "While the guidelines focus on duration of DAPT, the general consensus for elective surgeries including CABG is to stop DAPT at least 5 days prior to surgery, with some exceptions made for very high risk patients.",
    "context": "|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\n|COR|LOE|RECOMMENDATION|\n|---|---|---|\n|I|C-LD|In patients with ACS being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).|\nIssues related to the timing of discontinuation of DAPT before CABG are beyond the scope of this update but are addressed in the 2011 CABG guideline (10). Figure 3 summarizes recommendations for the management and duration of P2Y12 inhibitor therapy in patients undergoing CABG.\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable",
    "ground_truth_context": "Issues and recommendations with regard to P2Y12 inhibitor \u201cpre-treatment,\u201d \u201cpreloading,\u201d and loading are beyond the scope of this document but are addressed in other guidelines."
  },
  {
    "question": "A 60-year-old male with a history of hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "options": [
      "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
      "Prescribe cough suppressants and monitor symptoms",
      "Perform a bronchoscopy to obtain lower respiratory secretions for culture",
      "Order a CT scan of the chest with contrast to rule out pulmonary embolism"
    ],
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context discusses the management of community-acquired pneumonia (CAP) and suggests that in adults with CAP, empiric antibiotic therapy is a standard approach. The patient in the question presents with symptoms consistent with CAP (persistent cough, fever, shortness of breath) and a chest X-ray showing a right lower lobe infiltrate, which aligns with the context's mention of pneumonia symptoms and radiographic confirmation. Therefore, starting empiric antibiotic therapy for CAP is the most appropriate next step, as it directly addresses the condition described in the context. Other options, such as performing a bronchoscopy or ordering a CT scan, are not supported by the context for initial management.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "context": "and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nIn Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\nWe suggest testing for Legionella urinary antigen and collecting lower respiratory tract secretions for Legionella culture on selective media or Legionella nucleic acid amplification testing in adults with severe CAP (conditional recommendation, low quality of evidence).\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay."
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "options": [
      "Use eGFR based solely on serum creatinine for drug dosing.",
      "Use equations that combine both creatinine and cystatin C for drug dosing.",
      "Immediately initiate dialysis",
      "Discontinue all medications until the patient's kidney function improves."
    ],
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context explicitly states that for most people and clinical settings, validated eGFR equations using serum creatinine (SCr) are appropriate for drug dosing (Practice Point 4.2.2). Therefore, using eGFR based solely on serum creatinine for drug dosing is directly supported by the context. Options B, C, and D are not supported by the context as the context does not mention the necessity of using cystatin C for drug dosing, nor does it suggest initiating dialysis or discontinuing all medications.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "context": "Practice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\nFor most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nFor assessment of CKD, it is relevant to compare the GFR according to a standard body size. For this reason, GFR estimating equations have been developed in units of ml/min per 1.73 m2. However, because drug clearance is more strongly associated with nonindexed eGFR (ml/min) than indexed eGFR",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated."
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "options": [
      "Intramuscular midazolam",
      "IV lorazepam",
      "IV phenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that intramuscular midazolam is established as efficacious at stopping seizures lasting at least 5 minutes and has superior effectiveness compared with IV options. Given that IV access is difficult to obtain for the patient, intramuscular administration is preferable. Therefore, the correct choice based on the context is intramuscular midazolam (Option A).",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "context": "or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A)."
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "options": [
      "Restrict fluid intake to manage ascites",
      "Initiate a high-protein, low-carbohydrate diet",
      "Start enteral nutrition with a standard formula",
      "Delay nutritional support until her liver function stabilizes"
    ],
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly mentions that in patients with severe alcoholic hepatitis, oral intake is consistently reduced, and supplemental nutrition improves infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake. It also states that enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis. Therefore, starting enteral nutrition with a standard formula is directly supported by the context as an initial nutritional recommendation. Other options are not supported by the context provided.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "context": "In patients with severe alcoholic hepatitis, oral intake is consistently reduced [110,111,142,181]. When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake [186e188]. Enteral\n20. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA cooperative study group #275. J Parenter Enteral Nutr 1995;19(4):258e65.\n40. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr\nA total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct\nintake [186e188]. Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury"
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "options": [
      "3 months",
      "6 months",
      "12 months",
      "24 months"
    ],
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly states that available evidence supports a DAPT duration of at least 12 months for patients with NSTE-ACS who have undergone revascularization, including PCI. Since the patient in the question underwent PCI with drug-eluting stent placement, the recommendation of continuing DAPT for at least 12 months applies directly to this scenario.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "context": "|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014."
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "options": [
      "Liothyronine (T3) monotherapy",
      "Combination of levothyroxine (T4) and liothyronine (T3)",
      "Levothyroxine (T4) monotherapy",
      "Thyroid-stimulating hormone (TSH) injection therapy"
    ],
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for patients older than 50-60 years with overt hypothyroidism, an L-thyroxine (levothyroxine) dose of 50 \u00b5g daily should be considered. The patient in the question is 68 years old and presents with symptoms and lab findings consistent with overt hypothyroidism (elevated TSH and low free T4). Therefore, the appropriate initial treatment is levothyroxine (T4) monotherapy, as directly supported by the context. Options A, B, and D are not mentioned or supported by the context for this specific patient scenario.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "context": "Treatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nPatients whose serum TSH levels exceed 10 mIU/L are at increased risk for heart failure and cardiovascular mortality, and should be considered for treatment with L-thyroxine. Grade B, BEL 1\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nWhen initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism\nWhen initiating therapy in young healthy adults with overt hypothyroidism, beginning treatment with full replacement doses should be considered. Grade B, BEL 2  \nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient."
  },
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 7-day history of cough, fever, and purulent nasal discharge. He reports no improvement with over-the-counter cold medications. What is the most appropriate next step in management?",
    "options": [
      "Initiate oral azithromycin for presumed community-acquired pneumonia (CAP)",
      "Prescribe a short course of oral prednisone for symptomatic relief",
      "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
      "Order a chest x-ray to evaluate for pneumonia"
    ],
    "correct_answer_text": "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for a severe presentation of acute bacterial rhinosinusitis (ABRS), characterized by high fever and purulent nasal discharge, clinicians should either offer watchful waiting or prescribe initial antibiotic therapy. The patient in the question presents with fever and purulent nasal discharge, which aligns with the severe symptoms described for ABRS. Therefore, beginning a course of amoxicillin with or without clavulanate is directly supported by the context as an appropriate management step for ABRS.",
    "reasoning_ground_truth": "The patient's symptoms of fever, purulent nasal discharge, and lack of improvement with over-the-counter medications suggest **acute bacterial rhinosinusitis (ABRS)**. The appropriate initial treatment is amoxicillin with or without clavulanate. While pneumonia is a differential, the primary presentation is consistent with ABRS.  Azithromycin is an alternative for penicillin allergies but is not the first-line treatment for ABRS.",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nhigh fever and purulent nasal discharge as a \u201csevere\u201d presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune\nimprove diagnostic accuracy for adult rhinosinusitis, promote appropriate use of ancillary tests to confirm diagnosis and guide management, and promote judicious use of systemic and topical therapy, which includes radiography, nasal endoscopy, computed tomography, and testing for allergy and immune\ncorroborate the diagnosis. 163 Examination of the middle meatus for purulence in the decongested state may strongly suggest ABRS and allows endoscopically guided culture.164",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used. Saline nasal irrigation and/or topical intranasal corticosteroids are recommended."
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension is started on a new medication for her blood pressure. After two weeks she returns to the clinic for follow up reporting muscle weakness. Her labs show an increase in serum potassium. What is the most appropriate next step?",
    "options": [
      "Discontinue the new blood pressure medication immediately.",
      "Add a potassium-binding agent and continue the medication, with dietary modification",
      "Refer to nephrology for hemodialysis evaluation",
      "Prescribe an oral diuretic and schedule a follow-up in one week"
    ],
    "correct_answer_text": "Add a potassium-binding agent and continue the medication, with dietary modification",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes monitoring serum potassium levels within 2\u20134 weeks after starting or changing the dose of a medication, particularly in patients with CKD. The patient in the question has an increase in serum potassium, indicating hyperkalemia. The context suggests reviewing concurrent drugs and correcting volume depletion in cases of hyperkalemia. Adding a potassium-binding agent and continuing the medication aligns with managing hyperkalemia while maintaining the treatment for hypertension, as discontinuing the medication immediately is not directly supported by the context. Therefore, option B is the most appropriate next step based on the provided context.",
    "reasoning_ground_truth": "The patient's hyperkalemia, likely from her new blood pressure medication, can often be managed without stopping the medication. The appropriate step would be to add a potassium-binding agent, implement individualized dietary approaches, and monitor potassium levels.  Discontinuing the medication should be considered as a last resort,.",
    "context": "Monitor serum creatinine and potassium (within 2\u20134 weeks after starting or changing dose)  \n|Normokalemia|Hyperkalemia|\u226530% decrease in eGFR|<30% decrease in eGFR|\n|---|---|---|---|\nPractice Point 3.6.2: Changes in BP, serum creatinine, and serum potassium should be checked within 2\u20134 weeks of initiation or increase in the dose of a RASi, depending on the current GFR and serum potassium.\nChanges in BP, serum creatinine, and serum potassium should be checked within 2\u20134 weeks of initiation or increase in the dose of a RASi, depending on the current GFR and serum potassium.\nPractice Point 4.1.2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings.\n|---|---|---|---|\n|Increase dose of ACEi or ARB or continue on maximally tolerated dose|\u2022 Review concurrent drugs|\u2022 Review for causes of AKI|\u2022 Correct volume depletion|",
    "ground_truth_context": "Hyperkalemia associated with RASi use can often be managed without stopping RASi. Individualized dietary approaches should be implemented for those with hyperkalemia."
  },
  {
    "question": "A 72-year-old male with a history of stable ischemic heart disease (SIHD) is being discharged after a recent hospitalization for pneumonia, He has been on dual antiplatelet therapy (DAPT) for 12 months following a percutaneous coronary intervention (PCI). What is the most appropriate duration of DAPT at this point?",
    "options": [
      "Continue DAPT for an additional 12 months.",
      "Stop DAPT and continue on aspirin alone.",
      "Reduce DAPT to single antiplatelet therapy with clopidogrel",
      "Reduce DAPT to single antiplatelet therapy with aspirin"
    ],
    "correct_answer_text": "Reduce DAPT to single antiplatelet therapy with aspirin",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context specifies that in patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months. Since the patient has already completed 12 months of DAPT, the minimum requirement has been met. Additionally, the context recommends a daily aspirin dose of 81 mg for patients treated with DAPT. Therefore, it is reasonable to reduce DAPT to single antiplatelet therapy with aspirin, as the continuation of clopidogrel is not explicitly supported beyond the initial 6 months in the context provided.",
    "reasoning_ground_truth": "For patients with a history of ACS greater than one year prior, and who have since been stable, their condition is considered SIHD. At this point the current recommendation is to continue treatment with Aspirin alone.",
    "context": "whom P2Y12 inhibitor therapy had been discontinued >1 year before enrollment in the study (42). On the basis of all studies of DAPT in post-MI patients, extended DAPT for P2Y12 inhibitor therapy in patients with SIHD.\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nin patients in whom P2Y12 inhibitor therapy had been discontinued >1 year before enrollment in the study (42). Decisions about treatment with and duration of DAPT in patients with ACS require a thoughtful assessment of the benefit/risk ratio, integration of study data, and consideration of patient",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD."
  },
  {
    "question": "A 30-year-old female presents to the emergency department with a generalized tonic-clonic seizure lasting 7 minutes. She has no prior history of seizures, and IV access has not yet been established. What is the most appropriate initial therapy?",
    "options": [
      "Intravenous lorazepam",
      "Intramuscular midazolam",
      "Intravenous fosphenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "According to the context, intramuscular midazolam is established as efficacious as initial therapy for adults with convulsive status epilepticus and is noted to have superior effectiveness compared to intravenous lorazepam. Since the patient has a seizure lasting 7 minutes and IV access has not yet been established, intramuscular midazolam is the most appropriate choice as it does not require IV access and is effective as initial therapy.",
    "reasoning_ground_truth": "In adults with convulsive status epilepticus and without established IV access, **intramuscular midazolam** is the recommended first-line therapy because it is efficacious and rapidly administered. Intravenous lorazepam is preferred if IV access is established. Fosphenytoin is second-line therapy. Rectal diazepam is an alternative when the preferred options are not available.",
    "context": "The algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nadults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intramuscular midazolam has superior effectiveness compared to intravenous lorazepam in adults",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A)."
  },
  {
    "question": "A 45-year-old male with a history of alcohol abuse presents with jaundice, ascites, and altered mental status. His labs indicate acute liver failure. He is hypotensive and requires volume resuscitation. What is the most appropriate fluid for volume resuscitation at this time?",
    "options": [
      "Normal saline",
      "Albumin",
      "Hypertonic saline",
      "Dextrose 5% in water"
    ],
    "correct_answer_text": "Normal saline",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context specifies that most patients with acute liver failure (ALF) are volume depleted at presentation and require crystalloid volume resuscitation. Normal saline is a type of crystalloid fluid, making it the most appropriate choice for volume resuscitation in this scenario. The context does not provide specific support for the use of albumin, hypertonic saline, or dextrose 5% in water for volume resuscitation in ALF patients.",
    "reasoning_ground_truth": "Normal saline is the appropriate first line treatment for hypotension in acute liver failure, prior to considering albumin, which should be considered as a drug rather than as a simple resuscitative solution.",
    "context": "or renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\nIn the cohort of patients with ascites due to subacute liver failure or acute Budd-Chiari syndrome, elevated intra-abdominal pressure may be present. This may alter response to volume loading, in addition to increasing risk of gut dysfunction and AKI, response to fluid resuscitation needs to be\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to\nStudies of microcirculatory resuscitation as opposed to pressures. Appropriate utilisation of VA status in patients with ALF and hypoxic hepatitis. In a few cases, there may also be evidence of a toxic liver syndrome with increased lung water and ARDS. Assessment of intra-abdominal lung water may",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution."
  },
  {
    "question": "A 60-year-old male with a history of primary open-angle glaucoma (POAG) has been using prescribed eye drops for the past year. During his annual ophthalmology visit, his intraocular pressure (IOP) is still elevated, and his optic nerve shows progressive damage. He reports variable adherence to his medication regimen. What is the most appropriate next step in management?",
    "options": [
      "Increase the dose of his current eye drops.",
      "Add a second medication to his current eye drops",
      "Review patient education materials and discuss adherence.",
      "Refer for surgical intervention immediately."
    ],
    "correct_answer_text": "Review patient education materials and discuss adherence.",
    "correct_answer_idx": 2.0,
    "model_answer": null,
    "model_answer_idx": null,
    "model_reasoning": "The context emphasizes the importance of controlling IOP and preventing optic nerve damage in managing POAG. It also highlights that stable optic nerve status and low IOP are crucial, and that adherence to medication is a key factor in achieving these goals. Given that the patient reports variable adherence to his medication regimen, the most appropriate next step is to address this issue. Option C, which involves reviewing patient education materials and discussing adherence, directly targets the problem of non-adherence and is supported by the context as a necessary step before considering changes in medication or surgical intervention.",
    "reasoning_ground_truth": "Patient education and adherence are crucial in the management of POAG. Before escalating therapy, it's essential to ensure the patient understands the importance of medication adherence and how to use them correctly.",
    "context": "Guidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH,\nThe goals of managing patients with POAG are to control IOP in a target range and to prevent progressive visual field and optic nerve/RNFL damage in order to preserve visual function and quality of life. The initial glaucoma evaluation includes all components of the comprehensive adult medical\n- Stable optic nerve status and low IOP occur for a prolonged period in a patient taking topical ocular hypotensive agents. Under these circumstances, a carefully monitored attempt to reduce the medical regimen may be appropriate.\npretreatment IOP by 25% or more has been shown to slow progression of POAG.70, 72-74, 81, 82 Choosing a lower target IOP can be justified if there is more severe optic nerve damage, if the damage is progressing rapidly, or if other risk factors such as family history, age, or disc hemorrhages are\nClinical trials have shown that lowering IOP reduces the risk of developing POAG and slows the progression of the disease. Medical, laser, and incisional surgical approaches exist to effectively lower IOP. Early diagnosis and treatment generally prevent visual disability.",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence."
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has been on methotrexate for three months. She reports improvement in joint pain, but still experiences morning stiffness and fatigue, indicating moderate disease activity. What is the most appropriate next step?",
    "options": [
      "Add a biologic DMARD to her current methotrexate.",
      "Increase the dose of methotrexate",
      "Add a short course of oral prednisone to the methotrexate.",
      "Continue methotrexate monotherapy for another 3 months"
    ],
    "correct_answer_text": "Continue methotrexate monotherapy for another 3 months",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context emphasizes the conditional recommendation of methotrexate over alternative DMARDs due to its role as an anchor treatment in RA and the lack of alternatives with similar efficacy and/or superior long-term safety profiles. It also suggests continuing all DMARDs at their current dose over a dose reduction. Given that the patient is already experiencing improvement in joint pain, continuing methotrexate monotherapy aligns with the context's recommendation to maintain the current treatment approach, especially since methotrexate is favored for its efficacy and safety profile.",
    "reasoning_ground_truth": "According to guidelines, initial treatment for moderate-to-high RA is with **methotrexate monotherapy** . A combination approach may be considered after a trial of methotrexate. This patient has not had an adequate trial on methotrexate as she is only 3 months into treatment and still showing moderate disease activity.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\n- Does switching to non-methotrexate DMARDs improve tolerability over increasing the dose of folic acid, or using folinic acid or using split dose or subcutaneous dosing, for RA patients with side effects when taking methotrexate?\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\nrecommendation is in favor of methotrexate because of its important role as an anchor treatment in RA and the lack of alternatives with similar efficacy and/or superior long-term safety profiles.",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD."
  },
  {
    "question": "A 22-year-old male presents with urethral discharge and dysuria for 3 days. A gram stain of the discharge shows gram-negative diplococci. Which of the following is the recommended treatment approach?",
    "options": [
      "Oral azithromycin monotherapy",
      "Intramuscular ceftriaxone and oral azithromycin",
      "Oral doxycycline for 7 days",
      "Oral ciprofloxacin for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone and oral azithromycin",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context mentions increasing the dosage of ceftriaxone for the treatment of N. gonorrhoeae and suggests considering azithromycin in certain cases. The presence of gram-negative diplococci in the gram stain is indicative of N. gonorrhoeae infection. The recommended treatment approach, based on the context, involves using ceftriaxone and azithromycin together, as indicated by the mention of \"Ceftriaxone 1 g IM + azithromycin 2 g orally x 1\" as a treatment option. Therefore, option B, which includes both intramuscular ceftriaxone and oral azithromycin, aligns with the context's treatment recommendations.",
    "reasoning_ground_truth": "For gonococcal infections, the recommended treatment is **intramuscular ceftriaxone plus oral azithromycin**. This combination is used to address potential resistance and co-infection with chlamydia.",
    "context": "C. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\nmg orally x 1; cefixime 800 mg orally x 1; cefixime 400 mg orally x 2; or gentamicin 240 mg IM x 1|Critical: Microbiological cure, clinical cure, N. gonorrhoeae antimicrobial in vitro resistance, compliance Important: STI complications, side-effects (including allergy, toxicity), quality of life,\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated\nGemifloxacin 320 mg orally + azithromycin 2 g orally x 1 Ceftriaxone 1 g IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + spectinomycin 2 g IM x 1 Azithromycin 2 g orally x 1|Critical: Microbiological cure, compliance, STI complications, clinical cure, N. gonorrhoeae antimicrobial in vitro",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies"
  },
  {
    "question": "A 65-year-old male, recently hospitalized for an acute exacerbation of COPD, is being considered for discharge. He has been immobile for most of his hospital stay and has no other identified risk factors for VTE. Which VTE prophylaxis is recommended?",
    "options": [
      "Pharmacologic prophylaxis with subcutaneous heparin",
      "Mechanical prophylaxis with intermittent pneumatic compression devices",
      "Both pharmacologic and mechanical prophylaxis",
      "No VTE prophylaxis required due to low risk."
    ],
    "correct_answer_text": "Pharmacologic prophylaxis with subcutaneous heparin",
    "correct_answer_idx": 0.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context provides a conditional recommendation against extending pharmacological prophylaxis after hospital discharge and suggests not using VTE prophylaxis routinely in outpatients with minor VTE risk factors. The patient in the question is being considered for discharge and has been immobile, which is a minor provoking factor. According to the context, since he has no other identified risk factors for VTE, no VTE prophylaxis is required due to his low risk.",
    "reasoning_ground_truth": "According to recommendations acutely ill medical patients such as those in this case,  should receive pharmacologic prophylaxis, such as heparin.",
    "context": "hospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\nShould extended-duration pharmacological VTE prophylaxis after discharge (ie, up to 30 or 40 days) vs in-hospital\u2013only pharmacological VTE prophylaxis be used in acutely ill hospitalized medical patients?\nShould any DOAC extended beyond hospital discharge vs non-DOAC VTE prophylaxis administered in hospital only be used in acutely ill medical patients?\nwith stroke who receive VTE prophylaxis.\nShould VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89"
  },
  {
    "question": "A 70-year-old female presents with cough, fever and shortness of breath. She is diagnosed with community-acquired pneumonia (CAP) and is admitted to the hospital. Her blood cultures taken on admission come back negative. What is the most appropriate step?",
    "options": [
      "Continue antibiotics for 7 days, regardless of clinical stability",
      "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
      "Discontinue antibiotics immediately due to negative blood culture results.",
      "Switch antibiotics to oral therapy."
    ],
    "correct_answer_text": "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context suggests that standard antibacterial treatment should be prescribed for adults with CAP who test positive for influenza, and there is an emphasis on assessing clinical stability. Although the blood cultures are negative, the context does not recommend discontinuing antibiotics immediately based on this result. Instead, it implies that antibiotics should be continued until clinical stability is achieved, aligning with option B, which states to continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days. This approach is consistent with the recommendation to ensure appropriate treatment duration based on clinical stability rather than solely on culture results.",
    "reasoning_ground_truth": "The duration of antibiotic therapy should be guided by a validated measure of clinical stability and continued for at least 5 days. Negative blood cultures do not indicate discontinuing treatment.",
    "context": "In Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis?\nobtaining sputum Gram stain and culture in all adults with CAP managed in the hospital setting. Whether to culture patients or not should be determined by individual clinicians on the basis of clinical presentation, local etiological considerations, and local antimicrobial stewardship processes.\nRecommendation. We recommend that standard antibacterial treatment be initially prescribed for adults with clinical and radiographic evidence of CAP who test positive for influenza in the inpatient and outpatient settings (strong recommendation, low quality of evidence).\nIn Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy?\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days."
  },
  {
    "question": "A 62-year-old man with a history of heavy alcohol use presents with new onset jaundice, ascites, and confusion. His labs are suggestive of acute liver failure (ALF). He is hemodynamically stable and is being admitted for ongoing care. Which of the following is the preferred approach for managing his encephalopathy?",
    "options": [
      "Start intravenous steroids to reduce cerebral edema.",
      "Initiate lactulose and rifaximin.",
      "Maintain serum osmolarity above 320 mOsmol using hypertonic saline.",
      "Monitor intracranial pressure (ICP) without intervention"
    ],
    "correct_answer_text": "Initiate lactulose and rifaximin.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of managing hepatic encephalopathy (HE) in patients with acute liver failure (ALF) and suggests that even mild HE can indicate a life-threatening situation. The standard treatment for HE, particularly in the context of liver failure, involves the use of lactulose and rifaximin to reduce ammonia levels and manage symptoms. The context does not support the use of intravenous steroids, hypertonic saline, or solely monitoring ICP without intervention for managing encephalopathy. Therefore, option B is directly supported by the context as the preferred approach.",
    "reasoning_ground_truth": "The preferred approach for treating hepatic encephalopathy in ALF involves **lactulose and rifaximin**, which reduce the production and absorption of neurotoxins. Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol. ICP should be monitored and treatment initiated as necessary using interventions such as hypertonic saline or intravenous mannitol.",
    "context": "- In patients with severe ALI, screen intensively for any signs of hepatic encephalopathy.\n- Exclude the presence of cirrhosis, alcohol induced liver injury or malignant infiltration of the liver.\nDevelopment of encephalopathy is of key prognostic importance, with onset indicating critically impaired liver function. In subacute presentations, even low grade transaminases, increasing bilirubin and INR and encephalopathy may indicate extremely poor prognosis (evidence level II-2, grade of\nbe considered for transfer to offer improved chances of survival. ALF is a rare clinical syndrome and the experience of specialised liver units is required to continually improve the outcome of these patients. Mental alterations may be subtle. Even mild HE can indicate a life-threatening situation\ncourse. In \u2018hyper-acute\u2019 liver failure the onset of hepatic encephalopathy (HE) occurs within seven days of the onset of jaundice and patients most often recover promptly with medical therapy alone or after transplantation or die soon after illness onset. Due to the short duration of illness in\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol with RRT as required."
  },
  {
    "question": "A 48-year-old female with a 10-year history of type 1 diabetes is being screened for chronic kidney disease (CKD). Which test should be used to start the screening process, given her history?",
    "options": [
      "Urine dipstick for protein",
      "Serum creatinine and calculate eGFR",
      "24-hour urine collection for albumin",
      "Kidney biopsy"
    ],
    "correct_answer_text": "Serum creatinine and calculate eGFR",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that testing for chronic kidney disease (CKD) should involve both urine albumin measurement and assessment of glomerular filtration rate (GFR). Among the options provided, \"Serum creatinine and calculate eGFR\" (Option B) directly aligns with the context's recommendation to assess GFR, which is a key component of CKD screening. The other options do not directly match the context's specified methods for CKD screening.",
    "reasoning_ground_truth": "The initial screening test for CKD is an **eGFR calculated using serum creatinine**. While urine albumin is part of CKD evaluation, eGFR is the initial and primary test used.",
    "context": "of CKD is often already apparent at this time. For T1D, screening is recommended commencing 5 years after diagnosis. A second important group includes people with recent AKI or acute kidney disease (AKD), particularly multiple episodes of AKI, and those who have been \u201cpartially diagnosed\u201d with CKD\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nThe highest priority conditions for CKD detection are hypertension, diabetes, and CVD, including heart failure. For diabetes, the ADA and KDIGO recommend annual screening of people with diabetes for CKD. CKD screening should start at diagnosis of T2D because evidence of CKD is often already\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr."
  },
  {
    "question": "A 78-year-old male is diagnosed with acute bacterial rhinosinusitis (ABRS). He has a known penicillin allergy. Which antibiotic is most appropriate?",
    "options": [
      "Oral amoxicillin/clavulanate",
      "Oral azithromycin",
      "Oral doxycycline",
      "Topical intranasal corticosteroids"
    ],
    "correct_answer_text": "Oral doxycycline",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy. Since the patient has a penicillin allergy, oral doxycycline (Option C) is the most appropriate choice according to the provided context. Options A and B are not mentioned as alternatives for penicillin-allergic patients, and Option D is not an antibiotic.",
    "reasoning_ground_truth": "For patients with a penicillin allergy, **doxycycline** is a recommended alternative for treating ABRS. Azithromycin may be considered as an alternative to doxycycline. While topical intranasal corticosteroids are recommended for symptom relief, they are not an alternative to antibiotics for ABRS.",
    "context": "|Acute bacterial rhinosinusitis (ABRS)|Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis fail to improve within 10 days or more beyond the onset of upper respiratory\nThe rationale for antibiotic therapy of ABRS is to eradicate bacterial infection from the sinuses, hasten resolution of symptoms, and enhance disease-specific quality of life. Antibiotic therapy should be efficacious, cost-effective, and result in minimal side effects. Dozens of RCTs have assessed\nFor penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy. Fluoroquinolones, however, are not recommended for first-line therapy of ABRS in patients without penicillin\nNational ambulatory care data from 2006 to 2010 revealed that rhinosinusitis accounted for more outpatient antibiotic prescriptions than any other diagnosis. Despite guidelines that encourage judicious antibiotic use for ARS, they are prescribed in about 82% of visits. From 2006 to 2010,\nmore or less from antibiotic therapy. Further, there is no conclusive evidence that increased age or allergic rhinitis predicts a prolonged or chronic course of ABRS or any evidence that older patients benefit more from antibiotic therapy.",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used."
  },
  {
    "question": "A 28-year-old pregnant female at 32 weeks gestation is admitted to the hospital with a first-time seizure lasting 8 minutes.  IV access has been obtained. What is the preferred initial treatment for her convulsive status epilepticus?",
    "options": [
      "Intravenous phenytoin",
      "Intramuscular midazolam",
      "Intravenous lorazepam",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intravenous lorazepam",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions various treatments for convulsive status epilepticus, including lorazepam, diazepam, phenytoin, and phenobarbital. However, it does not specify which is preferred for a pregnant woman. Despite this, the context implies that intravenous administration is a common approach, as it lists intravenous lorazepam and phenytoin. Given the options, intravenous lorazepam (Option C) is a standard initial treatment for status epilepticus and is directly supported by the context as a viable intravenous option. Other options like intramuscular midazolam and rectal diazepam are not mentioned in the context as preferred initial treatments.",
    "reasoning_ground_truth": "For a patient with convulsive status epilepticus with established IV access, **intravenous lorazepam** is the recommended initial therapy. Intramuscular midazolam is preferred when IV access has not yet been established. Phenytoin is an acceptable alternative second line medication. Rectal diazepam is considered an alternative when the preferred options are not available.",
    "context": "The optimal pharmacologic treatment for early convulsive status epilepticus is unclear.\nwill lead to improvement in healthcare outcomes for people with convulsive status epilepticus.\n2. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America\u2019s Working Group on Status Epilepticus. JAMA 1993;270:854\u2013859.\n3. Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? Ann Neurol 2001;49:659\u2013664.\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC\nFIGURE 1. Proposed treatment algorithm for status epilepticus.",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A)."
  },
  {
    "question": "A 52-year-old male with a history of chronic liver disease presents with worsening ascites and is being evaluated for possible liver transplant. What type of renal replacement therapy (RRT) is preferred if the patient develops acute kidney injury?",
    "options": [
      "Intermittent hemodialysis",
      "Continuous renal replacement therapy (CRRT)",
      "Peritoneal dialysis",
      "No RRT is indicated at this time"
    ],
    "correct_answer_text": "Continuous renal replacement therapy (CRRT)",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context explicitly states that continuous RRT should always be undertaken in critically ill patients with acute liver failure (ALF), as opposed to intermittent RRT. Given that the patient has a history of chronic liver disease and is being evaluated for a liver transplant, it is reasonable to infer that if he develops acute kidney injury, he would be considered critically ill. Therefore, continuous renal replacement therapy (CRRT) is the preferred option according to the provided context.",
    "reasoning_ground_truth": "For patients with acute liver failure and acute kidney injury, **continuous renal replacement therapy (CRRT)** is preferred over intermittent hemodialysis to avoid metabolic and hemodynamic fluctuations.",
    "context": "Continuous RRT should always be undertaken in the critically ill patient with ALF as opposed to intermittent [222]. The role of additional supportive therapies such as tranexamic acid should also be considered in this context.\nConsider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15\u201320 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.\nPractice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15\u201320 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.\nA 2-year kidney failure risk threshold of >40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations.\nA 2-year kidney failure risk threshold of >40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations."
  },
  {
    "question": "A 68-year-old male with established primary open-angle glaucoma (POAG) is using a single eye drop medication. His intraocular pressure (IOP) remains elevated at his follow up appointment. What is the next step in the treatment of this patient?",
    "options": [
      "Increase the dose of his current eye drop",
      "Add a second medication to his current eye drop",
      "Consider laser trabeculoplasty",
      "Consider surgery."
    ],
    "correct_answer_text": "Add a second medication to his current eye drop",
    "correct_answer_idx": 1.0,
    "model_answer": null,
    "model_answer_idx": null,
    "model_reasoning": "The context states that if a drug fails to reduce IOP sufficiently, either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained. Since the patient is already using a single eye drop medication and his IOP remains elevated, adding a second medication is a directly supported next step according to the context.",
    "reasoning_ground_truth": "When a single medication is not adequate to manage POAG, adding a second medication is the preferred next step in management before considering laser trabeculoplasty or surgery.",
    "context": "If a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347,\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and\nOphthalmologists can lower IOP with medications, laser therapy, or incisional surgery. Results from randomized controlled trials (summarized in Table 2) and other studies provide evidence that these treatments reduce IOP and decrease the rate and incidence of progressive POAG.8, 25, 70-75, 79, 80,\nA reasonable initial treatment goal in a POAG patient is to reduce IOP 20% to 30% below baseline and to adjust up or down as indicated by disease course and severity.  \nP795\n- Stable optic nerve status and low IOP occur for a prolonged period in a patient taking topical ocular hypotensive agents. Under these circumstances, a carefully monitored attempt to reduce the medical regimen may be appropriate.",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence."
  },
  {
    "question": "A 58-year-old female with rheumatoid arthritis (RA) is currently treated with methotrexate, but is still having persistent moderate disease activity. Which of the following is the next recommended step?",
    "options": [
      "Add a targeted synthetic DMARD (tsDMARD)",
      "Increase the dose of methotrexate",
      "Add a biologic DMARD (bDMARD)",
      "Add a short course of oral prednisone"
    ],
    "correct_answer_text": "Add a biologic DMARD (bDMARD)",
    "correct_answer_idx": 2.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that methotrexate is conditionally recommended over alternative DMARDs for patients with moderate-to-high disease activity. Additionally, a split dose of oral methotrexate or an increased dose of folic/folinic acid is recommended over switching to alternative DMARDs for patients not tolerating oral weekly methotrexate. Therefore, increasing the dose of methotrexate aligns with the context's emphasis on maintaining methotrexate as a primary treatment option due to its efficacy and safety profile.",
    "reasoning_ground_truth": "According to the guidelines, if a patient on methotrexate monotherapy continues to have moderate disease activity, the next recommended step would be to add a **biologic DMARD** or a targeted synthetic DMARD.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\nrecommendation is in favor of methotrexate because of its important role as an anchor treatment in RA and the lack of alternatives with similar efficacy and/or superior long-term safety profiles.",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD."
  },
  {
    "question": "A 26-year-old male is diagnosed with uncomplicated gonorrhea. He has no known drug allergies. What is the recommended treatment regimen?",
    "options": [
      "Oral azithromycin 1 gram single dose",
      "Oral doxycycline 100 mg twice daily for 7 days",
      "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
      "Oral ciprofloxacin 500mg twice daily for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions increasing the dosage of ceftriaxone to 250 mg for the treatment of N. gonorrhoeae, which implies that ceftriaxone is a recommended treatment for gonorrhea. Although the context does not explicitly state the exact dosage of 500 mg, it aligns with the standard practice of using ceftriaxone for gonorrhea treatment. Additionally, the context discusses the use of azithromycin in combination with other treatments, supporting the combination of ceftriaxone and azithromycin. Therefore, option C, which includes intramuscular ceftriaxone and oral azithromycin, is the most directly supported by the context provided.",
    "reasoning_ground_truth": "For uncomplicated gonorrhea, the current recommendation is **intramuscular ceftriaxone plus oral azithromycin**, given as a single dose.",
    "context": "C. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\n|Adults and adolescents with treatment failure of N. gonorrhoeae (genital or oropharyngeal) to cephalosporins|Gentamicin 240 mg IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + azithromycin 1 g orally x 1 Spectinomycin 2 g IM + azithromycin 2 g orally x 1 Gemifloxacin 320 mg orally +\nGemifloxacin 320 mg orally + azithromycin 2 g orally x 1 Ceftriaxone 1 g IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + spectinomycin 2 g IM x 1 Azithromycin 2 g orally x 1|Critical: Microbiological cure, compliance, STI complications, clinical cure, N. gonorrhoeae antimicrobial in vitro\nmg orally x 1; cefixime 800 mg orally x 1; cefixime 400 mg orally x 2; or gentamicin 240 mg IM x 1|Critical: Microbiological cure, clinical cure, N. gonorrhoeae antimicrobial in vitro resistance, compliance Important: STI complications, side-effects (including allergy, toxicity), quality of life,",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies"
  },
  {
    "question": "A 55-year-old female is hospitalized for an acute illness. She has no prior history of venous thromboembolism (VTE). She is being considered for discharge. What should the VTE risk stratification for her take into account?",
    "options": [
      "Her age alone",
      "Her length of stay alone.",
      "Her risk factors for VTE and length of stay.",
      "Her comorbidities alone."
    ],
    "correct_answer_text": "Her risk factors for VTE and length of stay.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context provides a list of risk factors for VTE, including age, immobilization, and ICU/CCU stay, among others. It also mentions that the risk of VTE persists for 45 to 60 days after hospital discharge. Therefore, when considering VTE risk stratification for the patient, it is important to take into account her risk factors for VTE (such as age and any other applicable factors) and her length of stay, as these are explicitly mentioned in the context as relevant to assessing VTE risk.",
    "reasoning_ground_truth": "VTE risk assessment considers **both risk factors for VTE and length of stay**. Age and comorbidities are risk factors that should also be considered along with the length of stay. ",
    "context": "risk factor for VTE, and \u223c40% have $3 risk factors. In a United States population-based study, hospital-acquired DVT and PE occurred in 1.3% and 0.4% of hospital admissions, respectively. The increased risk of VTE persists for 45 to 60 days after hospital discharge. Other medical populations that\n|Previous VTE|3|\n|Known thrombophilia\u2021|2|\n|Lower limb paralysis\u00a7|2|\n|Active cancer|2|\n|Immobilization $7 d|1|\n|ICU/CCU stay|1|\n|Age .60 y|1|\n|IMPROVE bleeding RAM: score \u20217 indicates high bleeding risk{| |\n|Renal failure (GFR 30-59 vs $60 mL/min per m 2)|1|\n|Male vs female|1|\n- Chronically ill medical inpatients or nursing home residents\n- Outpatients with minor provoking VTE risk factors\n- Acutely or critically ill medical inpatients\n- Travelers\nVTE in hospitalized and nonhospitalized medical patients and long-distance travelers confers an important disease burden and can be fatal. About 50% of all VTE events in the community occur as a result of a current or recent hospital admission, mainly for surgery (24%) or acute medical illness\nOther nonhospitalized medical populations that are at increased risk for VTE include long-term care residents, frail persons, those with minor injuries, and long-distance travelers, particularly those with preexisting VTE risk factors. These guidelines addressed methods to prevent VTE in these",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89"
  },
  {
    "question": "A 67-year-old male with a history of COPD and recent hospitalization for pneumonia is now clinically stable and ready for discharge. What is the recommended duration for his antibiotic treatment?",
    "options": [
      "Continue antibiotics for 7 days.",
      "Continue antibiotics for 10 days.",
      "Continue antibiotics until clinical stability is achieved and for at least 5 days",
      "Discontinue antibiotics at the time of discharge."
    ],
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that antibiotic therapy should be continued until the patient achieves clinical stability and for no less than a total of 5 days. It mentions that most patients will achieve clinical stability within the first 48 to 72 hours, but treatment should still continue for at least 5 days. Therefore, the recommended duration for the patient's antibiotic treatment is until clinical stability is achieved and for at least 5 days, which aligns with option C.",
    "reasoning_ground_truth": "Antibiotic therapy for pneumonia should be continued **until a validated measure of clinical stability has been achieved and for no less than 5 days**. Specific duration of treatment based on set number of days, without regard for stability, is not recommended, nor is discontinuing at discharge, unless at least 5 days of antibiotics have already been completed and the patient is clinically stable.",
    "context": "In Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a\nor proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines (166).\nand normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days."
  },
  {
    "question": "A 57-year-old male with a long history of heavy alcohol use presents with worsening jaundice, ascites, and new onset confusion. He is diagnosed with acute liver failure (ALF). The patient's family is concerned about the development of intracranial pressure (ICP). What intervention should the health team implement to manage elevated ICP in this situation?",
    "options": [
      "Initiate intravenous dexamethasone",
      "Administer intravenous mannitol or hypertonic saline.",
      "Reduce the amount of IV fluids to decrease fluid overload.",
      "Administer intravenous albumin to increase intravascular volume."
    ],
    "correct_answer_text": "Administer intravenous mannitol or hypertonic saline.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context mentions that patients with hyper-acute ALF and elevated arterial ammonia levels are at increased risk of cerebral edema and intracranial hypertension (ICH). In such cases, managing elevated ICP is crucial. The use of intravenous mannitol or hypertonic saline is a common intervention to reduce cerebral edema and manage elevated ICP, which aligns with the context's focus on addressing intracranial hypertension. Other options like dexamethasone, reducing IV fluids, or administering albumin are not directly supported by the context for managing elevated ICP in ALF.",
    "reasoning_ground_truth": "The use of **hypertonic saline or intravenous mannitol** is recommended to treat sustained surges in ICP. Steroids are not recommended for treatment of elevated ICP in ALF. The purpose of fluid bolus in these cases is to increase stroke volume and cardiac output rather than volume resuscitation.",
    "context": "- In patients with severe ALI, screen intensively for any signs of hepatic encephalopathy.\n- Exclude the presence of cirrhosis, alcohol induced liver injury or malignant infiltration of the liver.\nPatients with hyper-acute ALF and elevated and sustained arterial ammonia levels (>150 mMol/l) may be at increased risk of cerebral edema and development of intra-cranial hypertension [177,178]. In this specific setting where there may be short-lived but current clinical practice adopted in many\nOne characteristic manifestation of ALF is the development of intracranial hypertension (ICH). These can manifest as a result of arterial hypertension, bradycardia and mydriasis in patients who have progressed to grade 3 or 4 coma.\n[220] Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005;11:1581\u20131589.\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF."
  },
  {
    "question": "A 60-year-old female with type 2 diabetes is being evaluated for chronic kidney disease (CKD). Her initial eGFR based on serum creatinine is 50 mL/min/1.73 m\u00b2. What is the next appropriate test for evaluation of her kidney function?",
    "options": [
      "Repeat serum creatinine measurement in 1 month",
      "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
      "24-hour urine collection for albumin",
      "Perform kidney biopsy"
    ],
    "correct_answer_text": "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of assessing both urine albumin measurement and glomerular filtration rate (GFR) for individuals at risk for chronic kidney disease (CKD). Since the initial eGFR is already provided, the next step should involve a more comprehensive evaluation of kidney function. Option B, which involves measuring cystatin C and calculating eGFR using both creatinine and cystatin C, aligns with the context's focus on thorough assessment of GFR. This approach provides a more accurate estimation of kidney function, as recommended by the guidelines. Other options, such as repeating serum creatinine measurement or performing a kidney biopsy, are not directly supported by the context for this scenario.",
    "reasoning_ground_truth": "If eGFR based on creatinine is thought to be inaccurate or a more accurate assessment of GFR is needed, the next step is to measure cystatin C and calculate the **eGFR using both creatinine and cystatin C**. 24 hour urine collection and kidney biopsy are not used as the next step but are used for other specific reasons.  ",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nfiltration rate (eGFR) should be monitored concurrently with serum potassium. Reproduced from Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1\u2013S127.",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated."
  },
  {
    "question": "A 75-year-old male with acute bacterial rhinosinusitis (ABRS) symptoms for 10 days, including purulent nasal discharge, facial pain, and fever, reports no improvement with initial saline irrigation. He is also started on amoxicillin/clavulanate. When should the patient be reassessed?",
    "options": [
      "Reassess in 1 week if symptoms are persistent.",
      "Reassess immediately if symptoms worsen",
      "Reassess in 2 weeks, or sooner if needed.",
      "Reassess only if complications develop."
    ],
    "correct_answer_text": "Reassess in 1 week if symptoms are persistent.",
    "correct_answer_idx": 0.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that ABRS symptoms should persist without improvement for at least 10 days to diagnose ABRS, and the patient has already been experiencing symptoms for 10 days. The context does not provide specific reassessment timelines, but given that the patient has been started on antibiotic therapy, a reasonable reassessment period would be in 2 weeks, or sooner if needed, to evaluate the effectiveness of the treatment. This aligns with option C, which suggests reassessing in 2 weeks or sooner if necessary, allowing time for the antibiotics to take effect while also providing flexibility for earlier reassessment if the patient's condition changes.",
    "reasoning_ground_truth": "Patients with ABRS should be reassessed **if symptoms persist after 7 days** on initial treatment, or if there is a worsening of symptoms.",
    "context": "ABRS when (a) symptoms or signs of acute rhinosinusitis persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms.\u201d\n|Acute bacterial rhinosinusitis (ABRS)|Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis fail to improve within 10 days or more beyond the onset of upper respiratory\nhigh fever and purulent nasal discharge as a \u201csevere\u201d presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset\nClinicians should confirm the diagnosis of ABRS by applying the diagnostic criteria in Table 4. If the patient does not have the symptom cluster of \u201cup to 4 weeks purulent nasal drainage . . . accompanied by nasal obstruction, facial pain-pressure-fullness, or both\u201d but instead has individual\nClinicians should distinguish presumed acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis caused by viral upper respiratory infections and noninfectious conditions. A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied",
    "ground_truth_context": "Define realistic expectations regarding clinical response to initial management and to articulate clearly when reassessment of the patient is warranted"
  },
  {
    "question": "A 35-year-old male in the hospital is experiencing a seizure. The seizure has lasted for 22 minutes and intravenous access has been established. He was treated with lorazepam at 5 minutes. What is the most appropriate next step in managing his status epilepticus?",
    "options": [
      "Repeat the intravenous lorazepam dose.",
      "Administer intravenous fosphenytoin.",
      "Administer intramuscular midazolam.",
      "Start a phenobarbital infusion."
    ],
    "correct_answer_text": "Administer intravenous fosphenytoin.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that if the seizure continues after the initial treatment with lorazepam, fosphenytoin is administered. Since the patient was treated with lorazepam at 5 minutes and the seizure has lasted for 22 minutes, the next appropriate step, as per the context, is to administer intravenous fosphenytoin.",
    "reasoning_ground_truth": "When a seizure continues after initial benzodiazepine therapy, the next recommended step is to administer a second line agent, such as fosphenytoin, valproic acid, or levetiracetam. Repeating the intravenous lorazepam dose is not preferred as the seizure has exceeded the initial therapy window and a second line therapy should be initiated.",
    "context": "lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\ncontinued another 7 more minutes, then fosphenytoin was given. There was no difference between IV diazepam (101/140, 72.1%) and IV lorazepam (97/133, 72.9%) in the primary efficacy outcome of termination of status epilepticus by 10 minutes (absolute difference of 0.8%, 95% CI: \u221211.4\u20139.8%). The\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nallowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes without recovery of consciousness. Overall, 205 patients were randomized",
    "ground_truth_context": "Reasonable options for second-line therapy include fosphenytoin, valproic acid, and levetiracetam."
  },
  {
    "question": "A 65 year old patient with known cirrhosis and newly diagnosed hepatic encephalopathy is admitted to the hospital. She is stable and has a history of medication intolerance. Which is the preferred medication for hepatic encephalopathy?",
    "options": [
      "Lactulose",
      "Rifaximin",
      "Intravenous steroids",
      "Oral neomycin"
    ],
    "correct_answer_text": "Lactulose",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context provided does not directly address hepatic encephalopathy or its treatment options. However, the question asks for the preferred medication for hepatic encephalopathy, and among the options given, lactulose (Option A) is a well-known treatment for this condition. The context does not mention any of the options directly, so the choice is based on the typical treatment approach for hepatic encephalopathy, which is lactulose.",
    "reasoning_ground_truth": "The preferred first line treatment for Hepatic encephalopathy is **Lactulose**. While Rifaximin may also be used, guidelines recommend starting with Lactulose. Intravenous steroids are not indicated in the management of HE. Oral neomycin is an alternative therapy but not first line. ",
    "context": "has been approved for severe Alzheimers disease. Memantine is approved by the FDA for treatment of moderate to severe Alzheimers disease. Available evidence for these medications remains modest. Several new studies of galantamine are available. In a trial by Burns and colleagues (2009) of patients\nIn addition to cholinesterase inhibitors and memantine the 2007 guideline reviews other medications used to delay the progression of cognitive symptoms in dementia including statins nonsteroidal anti-inflammatory drugs (NSAIDs) estrogen supplements and other marketed and experimental agents. Since\nwas found in a randomized placebo-controlled trial of memantine and vitamin E in 613 patients with mild to moderate Alzheimer's disease (Dysken et al. 2014) as described in more detail in the section Alternative Treatments.\nSince 2007 new randomized controlled trials of the cholinesterase inhibitors and memantine have been conducted to treat cognitive symptoms of dementia. The following sections review these new trials in patients with specific dementias (i.e. Alzheimers disease, vascular dementia and other dementias).\nTreatment of dementia with cholinesterase inhibitors and memantine can result in statistically significant but clinically marginal improvement in measures of cognition and global assessment of dementia (Raina et al. 2008 p. 379). New information is also available on adverse effects of",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations. Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF."
  },
  {
    "question": "A 50-year-old female with a diagnosis of primary open-angle glaucoma (POAG) has been treated with two different eye drop medications, but her intraocular pressure (IOP) is still not well controlled. What is the next step in her management?",
    "options": [
      "Consider laser trabeculoplasty",
      "Increase the dose of the current eye drops",
      "Add a third eye drop medication",
      "Refer for glaucoma surgery immediately"
    ],
    "correct_answer_text": "Consider laser trabeculoplasty",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that if a drug fails to reduce IOP sufficiently, switching to an alternative medication or adding medication is appropriate. However, it also mentions that adding a second medication decreased adherence to glaucoma treatment. Since the patient is already on two medications and her IOP is not well controlled, adding a third medication (option C) might further decrease adherence. The context also lists laser therapy as an option to lower IOP, making option A (consider laser trabeculoplasty) a viable next step. Increasing the dose of the current eye drops (option B) is not mentioned as a strategy in the context, and immediate referral for surgery (option D) is not suggested as the next step. Therefore, considering laser trabeculoplasty is the most contextually supported option.",
    "reasoning_ground_truth": "When medications do not adequately control IOP, **laser trabeculoplasty** is the next logical step to be considered before surgery is considered. While adding another eye drop medication is an option, it is not the preferred first step after initial treatment with two eye drop medications.",
    "context": "If a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347,\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and\nOphthalmologists can lower IOP with medications, laser therapy, or incisional surgery. Results from randomized controlled trials (summarized in Table 2) and other studies provide evidence that these treatments reduce IOP and decrease the rate and incidence of progressive POAG.8, 25, 70-75, 79, 80,\nA reasonable initial treatment goal in a POAG patient is to reduce IOP 20% to 30% below baseline and to adjust up or down as indicated by disease course and severity.  \nP795\npretreatment IOP by 25% or more has been shown to slow progression of POAG.70, 72-74, 81, 82 Choosing a lower target IOP can be justified if there is more severe optic nerve damage, if the damage is progressing rapidly, or if other risk factors such as family history, age, or disc hemorrhages are",
    "ground_truth_context": "Patients should receive proper professional support and referrals when their conditions fail to respond to treatment."
  },
  {
    "question": "A 45-year-old male with rheumatoid arthritis (RA) is on methotrexate monotherapy, but is still having moderate disease activity. He is now being started on a biologic DMARD (bDMARD). What is the best way to approach his current methotrexate therapy?",
    "options": [
      "Discontinue methotrexate at the time of starting the bDMARD",
      "Reduce the dose of methotrexate while starting the bDMARD",
      "Continue methotrexate at the same dose when starting the bDMARD",
      "Stop methotrexate and start the bDMARD"
    ],
    "correct_answer_text": "Continue methotrexate at the same dose when starting the bDMARD",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context suggests that methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD due to concerns about increased efficacy and risks of toxicity. However, it does not explicitly recommend discontinuing methotrexate when starting a bDMARD. Additionally, the context mentions a treat-to-target approach, which involves dose optimization of methotrexate and the subsequent addition of DMARDs when required. This implies that continuing methotrexate at the same dose while starting a bDMARD aligns with the treat-to-target strategy, as it allows for dose optimization and combination therapy to achieve better disease control. Therefore, option C is directly supported by the context.",
    "reasoning_ground_truth": "According to guidelines, when adding a bDMARD to methotrexate therapy, the recommendation is to **continue methotrexate at the current dose**. Discontinuation or reducing the dose of methotrexate is not recommended at this time.",
    "context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD physician and patient preferences regarding the tradeoff between the increased efficacy and risks of toxicity associated with higher starting doses. This recommendation refers only to\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\nMethotrexate monotherapy is strongly recommended over bDMARD or tsDMARD monotherapy for DMARD-naive patients with moderate-to-high disease activity. There is low-certainty evidence suggesting superiority of tocilizumab monotherapy (15) over methotrexate monotherapy and moderate-certainty evidence\nA treat-to-target approach is strongly recommended over usual care for patients who have not been previously treated with bDMARDs or tsDMARDs. This recommendation applies to dose optimization of methotrexate and to the subsequent addition of DMARDs when required. The recommendation is strong despite\n|Combination of methotrexate plus a non\u2013TNF inhibitor bDMARD or tsDMARD\u00b6|Low/very low|PICO 6a.C2\u20134/C5\u00a7|p. 109, 117\u201328|\n|Methotrexate monotherapy is conditionally recommended over:| | | |\n|Leflunomide|Low|PICO 2a.C3|p. 18|\n|Dual or triple csDMARD therapy\u00b6|Moderate|PICO 4a.C1\u2013C2|p. 46\u20139|",
    "ground_truth_context": "Continuation of DMARDs at the current dose is preferred over dose reduction, which is preferred over gradual discontinuation, which is preferred over abrupt discontinuation."
  },
  {
    "question": "A 28-year-old male presents to the clinic with concern for possible gonorrhea. He reports a recent unprotected sexual encounter.  What is the preferred initial treatment if he is diagnosed with gonorrhea?",
    "options": [
      "Oral azithromycin 1 gram single dose",
      "Oral doxycycline 100mg twice daily for 7 days",
      "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
      "Oral ciprofloxacin 500 mg twice daily for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions increasing the dosage of ceftriaxone for the treatment of N. gonorrhoeae and suggests dual therapy due to the emergence of resistance. Although the specific dosage of ceftriaxone mentioned in the context is 250 mg, the question asks for the preferred initial treatment, which aligns with the dual therapy approach. Option C, which includes intramuscular ceftriaxone and oral azithromycin, fits the context's emphasis on dual therapy for gonorrhea. Other options do not align with the context's recommendations for dual therapy or the specific treatments mentioned.",
    "reasoning_ground_truth": "The recommended initial treatment for gonorrhea is a single dose of **intramuscular ceftriaxone along with a single dose of oral azithromycin**.",
    "context": "C. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\nthe eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even\nan option for treatment of gonococcal infections. The GDG agreed that dual therapy should be suggested due to the emergence of resistance and the paucity of surveillance data in most settings to guide decisions about susceptibility to single therapy. Additional studies comparing different\nmg orally x 1; cefixime 800 mg orally x 1; cefixime 400 mg orally x 2; or gentamicin 240 mg IM x 1|Critical: Microbiological cure, clinical cure, N. gonorrhoeae antimicrobial in vitro resistance, compliance Important: STI complications, side-effects (including allergy, toxicity), quality of life,",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies"
  },
  {
    "question": "A 70-year-old patient is admitted to the hospital for an acute medical illness. They have limited mobility during the admission. What is the preferred initial method of VTE prophylaxis?",
    "options": [
      "Mechanical prophylaxis with graduated compression stockings",
      "Mechanical prophylaxis with intermittent pneumatic compression",
      "Pharmacological prophylaxis with LMWH or UFH",
      "No prophylaxis is necessary due to limited VTE risk."
    ],
    "correct_answer_text": "Pharmacological prophylaxis with LMWH or UFH",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses the use of pharmacological VTE prophylaxis for acutely ill hospitalized medical patients, indicating that it is a consideration during hospital admission. It specifically mentions the debate over extending pharmacological prophylaxis after discharge, implying that pharmacological methods are indeed used during hospitalization. Therefore, for a 70-year-old patient admitted with an acute medical illness and limited mobility, pharmacological prophylaxis with LMWH or UFH is the preferred initial method, as it aligns with the context's focus on in-hospital pharmacological VTE prophylaxis.",
    "reasoning_ground_truth": "For acutely ill medical patients, guidelines recommend **pharmacologic prophylaxis with a low molecular weight heparin (LMWH) or unfractionated heparin (UFH)**. Mechanical prophylaxis can be used in certain situations, but is not the preferred initial method",
    "context": "Should extended-duration pharmacological VTE prophylaxis after discharge (ie, up to 30 or 40 days) vs in-hospital\u2013only pharmacological VTE prophylaxis be used in acutely ill hospitalized medical patients?\nShould VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nShould pharmacological VTE prophylaxis be used in chronically ill medical patients or nursing home patients?\nhospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\nwith stroke who receive VTE prophylaxis.",
    "ground_truth_context": "LMWH vs UFH in acutely ill medical patients. Summary of the evidence. We found 8 systematic reviews51,52,54,58,59,63,65,67 that addressed this question and included 11 RCTs."
  },
  {
    "question": "A 54 year-old male is admitted to the hospital with community-acquired pneumonia (CAP). His blood cultures are negative, and his symptoms are improving after 3 days of intravenous antibiotics. How long should he continue antibiotic therapy?",
    "options": [
      "Continue intravenous antibiotics for 7 days",
      "Switch to oral antibiotics for 7 days",
      "Continue intravenous antibiotics until clinical stability and then for 2 additional days",
      "Continue antibiotics until clinical stability is achieved and for at least 5 days"
    ],
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context suggests that most studies support a 5-day antibiotic therapy duration for CAP patients who are improving, even if they have severe CAP without infectious complications. The patient in the question is improving after 3 days of treatment, and the context implies that therapy should continue until clinical stability is achieved and for at least 5 days. Therefore, option D aligns with the context, as it specifies continuing antibiotics until clinical stability and for at least 5 days.",
    "reasoning_ground_truth": "Antibiotic therapy for CAP should be continued until the patient achieves **clinical stability and for at least 5 days**. The route of administration of the antibiotic should be based on the patient\u2019s ability to tolerate oral intake.",
    "context": "In Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nWe acknowledge that most studies in support of 5 days of antibiotic therapy include patients without severe CAP, but we believe these results apply to patients with severe CAP and without infectious complications. We believe that the duration of therapy for CAP due to suspected or proven MRSA or P.\nIn Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy?\nControlled studies are needed to establish the duration of antibiotic therapy for adults with complications of CAP, including empyema, and adults with prolonged time to achieving clinical stability.\nFinally, routine cultures in patients empirically treated for MRSA or P. aeruginosa allow deescalation to standard CAP therapy if cultures do not reveal a drug-resistant pathogen and the patient is clinically improving at 48 hours.",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days."
  },
  {
    "question": "A 45-year-old female with chronic rhinosinusitis (CRS) presents with persistent nasal congestion and facial pain despite using saline nasal irrigation and topical corticosteroids. She reports no history of allergies. What is the next most appropriate step in her management?",
    "options": [
      "Prescribe a course of oral antibiotics.",
      "Recommend allergy testing and consider immunotherapy.",
      "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
      "Obtain a CT scan of the sinuses to assess for anatomical abnormalities."
    ],
    "correct_answer_text": "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
    "correct_answer_idx": 2,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of confirming a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Since the patient is already using saline nasal irrigation and topical corticosteroids without relief, the next step should be to obtain objective evidence of sinonasal inflammation. Option C, performing nasal endoscopy, aligns directly with this recommendation from the context.",
    "reasoning_ground_truth": "The patient has persistent CRS despite initial management, it is important to obtain objective evidence of sinonasal inflammation, and evaluate for nasal polyps by nasal endoscopy. Antibiotics are not a primary treatment for CRS. Allergy testing may be considered, but an objective confirmation of CRS should be prioritized. CT scan is an option for objective documentation but nasal endoscopy is a more appropriate first-line diagnostic step.",
    "context": "|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nwithin the sinuses. Therefore, when CRS is present, it should be treated with medications and other therapies that will target the underlying inflammatory disorder.\nA beneficial effect of nasal irrigation for symptomatic relief of CRS has been shown in a Cochrane review 264 and in other systematic reviews.258,265 Nasal saline irrigation is effective as sole treatment for CRS or as an adjunct to topical nasal steroids, but compared directly with topical nasal\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS. Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS."
  },
  {
    "question": "A 52-year-old male, post-stent placement for stable ischemic heart disease (SIHD) 6 months ago, is scheduled for an elective cholecystectomy. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the most appropriate perioperative management of his antiplatelet therapy?",
    "options": [
      "Continue both aspirin and clopidogrel throughout the perioperative period.",
      "Discontinue both aspirin and clopidogrel 5 days before surgery.",
      "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
      "Discontinue aspirin and continue clopidogrel throughout the perioperative period."
    ],
    "correct_answer_text": "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly recommends that if P2Y12 inhibitor therapy (such as clopidogrel) needs to be held in patients being treated with DAPT after stent implantation, the continuation of aspirin therapy is recommended if possible. Therefore, the most appropriate perioperative management is to continue aspirin and discontinue clopidogrel 5 days prior to surgery, aligning with option C.",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective surgery, it is generally recommended to continue aspirin and discontinue the P2Y12 inhibitor (in this case, clopidogrel) 5 days prior to surgery to reduce the risk of bleeding. Stopping both medications increases the risk of thrombotic events. Continuing both medications increases bleeding risk",
    "context": "|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as\nThe magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158). If P2Y12 inhibitor therapy needs to be held in patients being treated with DAPT after stent implantation, continuation of aspirin therapy if possible is recommended,\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nIntensification of antiplatelet therapy, with the addition of a P2Y12 inhibitor to aspirin monotherapy, as well as prolongation of DAPT, necessitates a fundamental tradeoff between decreasing ischemic risk and increasing bleeding risk. Decisions about treatment with and duration of DAPT require a\nDAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. 5 High bleeding risk denotes those who have or develop a high risk of",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery"
  },
  {
    "question": "A 68-year-old female presents with a 3-day history of fever, cough, and purulent nasal discharge. She has a history of well-controlled asthma. She reports her symptoms began after a recent cold and is concerned about a sinus infection. What is the most appropriate next step in her management?",
    "options": [
      "Start empiric antibiotics immediately",
      "Obtain a sinus CT to determine extent of infection.",
      "Recommend symptomatic relief and observe her symptoms for 7 days.",
      "Prescribe oral corticosteroids to manage inflammation."
    ],
    "correct_answer_text": "Recommend symptomatic relief and observe her symptoms for 7 days.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context suggests that clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for rhinosinusitis. However, it also emphasizes the importance of assessing the patient for chronic conditions that might modify management, such as asthma, and considering the patient's general health and comorbid conditions. Since the patient has a history of well-controlled asthma and her symptoms have only been present for 3 days, the context supports recommending symptomatic relief and observing her symptoms for 7 days, aligning with the watchful waiting approach. This is consistent with the context's guidance to promote judicious use of systemic therapy and to consider the patient's overall health status.",
    "reasoning_ground_truth": "The patient has symptoms for 3 days, which is not long enough to diagnose ABRS. Given that her symptoms developed after a cold, it is likely a viral rhinosinusitis (VRS), symptomatic relief is the best option. Antibiotics are not indicated at this time, nor are CT scans or oral corticosteroids. It would be appropriate to reassess if symptoms worsen.",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nClinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune\n- Exceptions: Include but are not limited to severe illness, complicated sinusitis, immune deficiency, prior sinus surgery, or coexisting bacterial illness; the clinician should also consider the patient\u2019s age, general health, cardiopulmonary status, and comorbid conditions in determining an\nimprove diagnostic accuracy for adult rhinosinusitis, promote appropriate use of ancillary tests to confirm diagnosis and guide management, and promote judicious use of systemic and topical therapy, which includes radiography, nasal endoscopy, computed tomography, and testing for allergy and immune",
    "ground_truth_context": "In contrast to the version of this statement in the original sinusitis guideline,1 we changed the diagnostic criteria to include not just the persistence of signs and symptoms beyond 10 days but failure to improve in 10 days, for greater specificity in distinguishing presumed bacterial infection for persistent, but resolving, viral illness. Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS."
  },
  {
    "question": "A 55-year-old male with a history of a myocardial infarction (MI) one year ago, treated with a drug-eluting stent, is currently on aspirin and clopidogrel. He has been free of any cardiac events since the procedure. Based on current guidelines, what is the recommended duration of dual antiplatelet therapy (DAPT)?",
    "options": [
      "Continue DAPT indefinitely.",
      "Continue DAPT for an additional 6 months.",
      "Discontinue clopidogrel and continue aspirin.",
      "Discontinue both aspirin and clopidogrel."
    ],
    "correct_answer_text": "Discontinue clopidogrel and continue aspirin.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that studies assessing the efficacy of DAPT compared with aspirin monotherapy were conducted 1 to 3 years after myocardial infarction (MI). It also mentions that extended DAPT resulted in reductions in certain risks, but the specific recommendations for DAPT duration are summarized in Figure 1, which suggests that after a certain period, aspirin monotherapy is considered. Since the patient has been free of cardiac events for one year, the context supports transitioning to aspirin monotherapy, aligning with option C: Discontinue clopidogrel and continue aspirin.",
    "reasoning_ground_truth": "For patients with a history of MI treated with a drug-eluting stent who are beyond one year without any cardiac events, they are considered to have stable ischemic heart disease. They can discontinue the P2Y12 inhibitor, (clopidogrel) and continue with single antiplatelet therapy, usually aspirin.",
    "context": "with DAPT for 12 months, and were without ischemic or bleeding events during this period were randomized to an additional 18 months of DAPT or to aspirin monotherapy (16). Extended DAPT resulted in a 0.7% absolute reduction in very late stent thrombosis, a 2.0% absolute reduction in MI, a 1.6%\nof patients 1 to 3 years after myocardial infarction (MI) assessing the efficacy of DAPT compared with aspirin monotherapy (28). These studies were published after the formulation of recommendations for duration of DAPT in prior guidelines. The specific mandate of the present writing group is to\nrecommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD."
  },
  {
    "question": "A 28-year-old female presents with a 2-day history of nasal congestion, clear nasal discharge, and mild facial pressure. She denies fever or purulent discharge. What is the most appropriate initial management?",
    "options": [
      "Prescribe an antibiotic to prevent a bacterial infection.",
      "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
      "Order a sinus CT scan to assess the extent of the sinus congestion.",
      "Prescribe a short course of oral corticosteroids."
    ],
    "correct_answer_text": "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that acute rhinosinusitis (ARS) is characterized by purulent nasal drainage, nasal obstruction, and facial pain-pressure-fullness. The patient in the question presents with clear nasal discharge, which does not meet the criteria for ARS as per the context. Therefore, prescribing antibiotics (Option A) is not appropriate since there is no indication of a bacterial infection. The context also mentions that nasal saline may be palliative and cleansing with low risk of adverse reactions, and analgesics can be given for pain relief. Thus, recommending analgesics, decongestants, and nasal saline irrigation for symptomatic relief (Option B) aligns with the context's guidance for managing symptoms without purulent discharge. Ordering a sinus CT scan (Option C) or prescribing oral corticosteroids (Option D) is not supported by the context for the symptoms described.",
    "reasoning_ground_truth": "The patient's symptoms are consistent with a viral rhinosinusitis (VRS). Antibiotics are not indicated for viral infections. A sinus CT scan is not necessary given the non-severe nature of her symptoms. Oral corticosteroids are not appropriate for the typical treatment of a viral rhinosinusitis. Symptomatic relief with analgesics, decongestants, and nasal saline irrigation is the most appropriate initial strategy.",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nAcute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS."
  },
  {
    "question": "A 65-year-old male with chronic rhinosinusitis (CRS) and nasal polyps has been using nasal saline irrigation and topical corticosteroids with minimal improvement. What is the most appropriate next step in management?",
    "options": [
      "Prescribe a 10-day course of oral antibiotics",
      "Order an allergy skin test to evaluate for allergic rhinitis",
      "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
      "Continue current therapy with close follow up."
    ],
    "correct_answer_text": "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the use of saline nasal irrigation and topical intranasal corticosteroids for symptom relief of CRS. It also mentions confirming the presence or absence of nasal polyps in a patient with CRS. Since the patient has minimal improvement with the current therapy, the next appropriate step, according to the context, is to confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist. This aligns with the context's guidance on managing CRS and nasal polyps. Options A and B are not supported by the context, and option D suggests continuing a therapy that is already minimally effective.",
    "reasoning_ground_truth": "Given his persistent symptoms despite initial therapy, it is important to confirm the diagnosis of CRS, and referral may be beneficial to assess other management strategies such as surgery. Oral antibiotics are not effective for CRS. Allergy testing can be considered, but the next priority is to confirm the diagnosis and further evaluate other treatment strategies",
    "context": "|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nA beneficial effect of nasal irrigation for symptomatic relief of CRS has been shown in a Cochrane review 264 and in other systematic reviews.258,265 Nasal saline irrigation is effective as sole treatment for CRS or as an adjunct to topical nasal steroids, but compared directly with topical nasal\ndyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\nTopical nasal steroids have been used alone or in combination with oral antibiotics for symptomatic relief of ABRS. Nasal saline irrigation, alone or in conjunction with other adjunctive measures, may improve quality of life, decrease symptoms, and decrease medication use for ABRS, particularly in\nThe purpose of this statement is to highlight the importance of intranasal saline and intranasal corticosteroid therapy in providing symptomatic relief and improved quality of life for patients with CRS. Despite the benefits of these interventions seen in RCTs and systematic reviews, the GUG felt",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS."
  },
  {
    "question": "A 70-year-old male with stable ischemic heart disease (SIHD) underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 3 months ago. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. He is now scheduled for a colonoscopy. What is the most appropriate perioperative management?",
    "options": [
      "Continue both aspirin and clopidogrel during the colonoscopy",
      "Stop both aspirin and clopidogrel 5 days prior to the colonoscopy",
      "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
      "Stop aspirin and continue clopidogrel during the colonoscopy"
    ],
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that in patients with SIHD treated with DAPT after DES implantation, clopidogrel should be given for at least 6 months. However, it also mentions that aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. Given that the patient is scheduled for a colonoscopy, a procedure that may require modification of antiplatelet therapy to reduce bleeding risk, the most appropriate management would be to continue aspirin (as it is recommended to be continued indefinitely) and stop clopidogrel, which is not yet at the 6-month mark but can be paused for the procedure. This aligns with the context's emphasis on the indefinite continuation of aspirin and the potential adjustment of clopidogrel in the perioperative setting.",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective procedures, guidelines recommend continuing aspirin and discontinuing the P2Y12 inhibitor, (clopidogrel) 5 days before the procedure to reduce bleeding risk while maintaining some protection against thrombotic events. Stopping both medications can increase risk of thrombotic events. Continuing both medications increases bleeding risk during the procedure",
    "context": "|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nDAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. 5 High bleeding risk denotes those who have or develop a high risk of\n|IIb|A SR|In patients with SIHD treated with BMS or DES implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1 month in\n|IIb|ASR|In patients with SIHD treated with DAPT after BMS or DES implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery"
  },
  {
    "question": "A 30-year-old patient presents with a 14-day history of persistent nasal congestion, facial pressure, and purulent nasal discharge. The patient has no fever, and their symptoms started after a cold. Based on these symptoms, what is the appropriate diagnosis?",
    "options": [
      "Viral rhinosinusitis (VRS).",
      "Acute bacterial rhinosinusitis (ABRS).",
      "Allergic rhinitis.",
      "Migraine headache."
    ],
    "correct_answer_text": "Acute bacterial rhinosinusitis (ABRS).",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context defines acute rhinosinusitis (ARS) as up to 4 weeks of purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both. The patient presents with a 14-day history (which is within 4 weeks) of purulent nasal discharge, nasal congestion, and facial pressure, which aligns with the definition of ARS. Since the symptoms are persistent and purulent, this suggests a bacterial cause, making acute bacterial rhinosinusitis (ABRS) the appropriate diagnosis. Options A, C, and D do not fit the context as they either do not involve purulent discharge or do not match the symptom profile described.",
    "reasoning_ground_truth": "The patient's symptoms of persistent nasal congestion, facial pressure, and purulent nasal discharge lasting over 10 days after a cold are highly suggestive of acute bacterial rhinosinusitis (ABRS). While VRS may present with similar symptoms, they typically resolve within 10 days. Allergic rhinitis and migraines do not typically present with purulent nasal discharge.",
    "context": "Acute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more\naccompany viral upper respiratory infection, and may be reported by the patient or observed on physical examination. Nasal obstruction may be reported by the patient as nasal obstruction, congestion, blockage, or stuffiness, or may be diagnosed by physical examination. Facial pain-pressure-fullness",
    "ground_truth_context": "A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening)."
  },
  {
    "question": "A 48-year-old male is diagnosed with chronic rhinosinusitis (CRS) based on his symptoms. To confirm the diagnosis, the clinician should obtain objective documentation of sinonasal inflammation. Which of the following is most appropriate to perform to confirm sinonasal inflammation?",
    "options": [
      "Allergy skin test.",
      "Sinus radiography.",
      "Anterior rhinoscopy or nasal endoscopy.",
      "Blood test for infection."
    ],
    "correct_answer_text": "Anterior rhinoscopy or nasal endoscopy.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly states that objective confirmation of sinonasal inflammation, necessary for diagnosing CRS, can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Among the given options, \"C. Anterior rhinoscopy or nasal endoscopy\" directly aligns with the methods mentioned in the context for confirming sinonasal inflammation. Other options like allergy skin test, sinus radiography, and blood test for infection are not mentioned as appropriate methods for this purpose in the provided context.",
    "reasoning_ground_truth": "To confirm a diagnosis of CRS, objective documentation of sinonasal inflammation is required. This can be achieved through direct visualization using anterior rhinoscopy or nasal endoscopy. While a CT scan is an option, it is usually not the first step. Allergy testing and blood tests for infection are not appropriate methods for confirming sinonasal inflammation.",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nThe purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation (Table 8). Requiring objective signs of inflammation increases diagnostic accuracy for CRS and serves to limit\nObjective confirmation of sinonasal inflammation may be made by direct visualization or by CT scanning. Direct visualization is best accomplished with nasal endoscopy, but in some patients, anterior rhinoscopy using an otoscope or nasal speculum may suffice. An important part of direct\nfor CRS and serves to limit overdiagnosis. Moreover, objective confirmation of inflammation will prevent unnecessary tests and interventions for individuals with self-reported sinonasal symptoms that can be readily mistaken for CRS, such as those caused by perennial allergic rhinitis.",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography."
  },
  {
    "question": "A 32-year-old male presents with a 5-day history of nasal congestion, facial pain, and clear nasal discharge following a cold. He denies fever or purulent discharge. What is the most appropriate initial treatment approach?",
    "options": [
      "Start empiric antibiotics for bacterial sinusitis.",
      "Prescribe oral corticosteroids to reduce inflammation.",
      "Recommend analgesics, decongestants, and nasal saline irrigation.",
      "Order a sinus CT scan to determine the severity of the infection."
    ],
    "correct_answer_text": "Recommend analgesics, decongestants, and nasal saline irrigation.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context describes that for sinonasal inflammation, adjunctive treatments such as analgesics, decongestants, and nasal saline irrigation may aid in symptomatic relief. The patient presents with clear nasal discharge, which is typically associated with viral upper respiratory infections rather than bacterial sinusitis. Therefore, starting antibiotics (Option A) is not supported by the context. Oral corticosteroids (Option B) are not mentioned as a recommended initial treatment in the context. Ordering a sinus CT scan (Option D) is not indicated for initial treatment, especially when symptoms are mild and consistent with a viral infection. Thus, recommending analgesics, decongestants, and nasal saline irrigation (Option C) aligns with the context's guidance for symptomatic relief.",
    "reasoning_ground_truth": "The patient's symptoms are indicative of a viral rhinosinusitis (VRS). Antibiotics are not indicated for a viral cause. Oral corticosteroids are not an initial therapy. A CT scan is not indicated. Symptomatic relief is the most appropriate first step",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS."
  },
  {
    "question": "A 55-year-old female with chronic rhinosinusitis (CRS) and nasal polyps has had minimal improvement with topical corticosteroids and saline irrigations. She has a history of mild asthma. What is the most appropriate next step in management?",
    "options": [
      "Prescribe a 10 day course of oral antibiotics.",
      "Recommend allergy testing.",
      "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
      "Obtain a sinus CT scan"
    ],
    "correct_answer_text": "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of identifying patients who might benefit from additional diagnostic tests to assess for conditions other than CRS that are associated with nasal polyposis. It also suggests prioritizing referral for specialty evaluation. Given the patient's history of mild asthma and minimal improvement with current treatments, evaluating for other conditions such as asthma that might modify management and considering an otolaryngology referral aligns directly with the context's recommendations. Options A and B are not supported by the context, and while D might seem plausible, the context prioritizes evaluation and referral over imaging.",
    "reasoning_ground_truth": "Given her persistent symptoms and history of asthma, it is important to consider other comorbid conditions that can modify the management of her CRS. Allergy testing and a CT can be considered, but the primary step is to evaluate for other conditions, such as asthma. Antibiotics are not a standard treatment for CRS.",
    "context": "|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\ndyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\nA systematic review found that endoscopic sinus surgery improves asthma control while decreasing asthma exacerbations, hospitalizations, and use of systemic and inhaled corticosteroids; pulmonary function, however, is unchanged. These findings suggest a benefit of prompt therapy for CRS in\n- Benefit: Prioritize referral for specialty evaluation, identify patients likely to benefit most from topical (intranasal) or systemic corticosteroid therapy, identify patients for additional diagnostic tests to assess for conditions other than CRS that are associated with nasal polyposis and may",
    "ground_truth_context": "Clinicians should assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia."
  },
  {
    "question": "A 70-year-old patient who underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 5 months ago for stable ischemic heart disease is currently on dual antiplatelet therapy (DAPT). He is scheduled for cataract surgery. What is the best way to manage his antiplatelet therapy?",
    "options": [
      "Continue both aspirin and clopidogrel for the surgery",
      "Stop both aspirin and clopidogrel 5 days before surgery",
      "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
      "Stop aspirin and continue clopidogrel during the surgery"
    ],
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "According to the context, in patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that require discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible. Therefore, option C, which suggests continuing aspirin and stopping clopidogrel 5 days prior to surgery, aligns with the context's recommendation.",
    "reasoning_ground_truth": "For patients with stable ischemic heart disease who are undergoing elective noncardiac surgery, guidelines recommend to continue aspirin and to stop the P2Y12 inhibitor, (clopidogrel) 5 days before surgery to balance the risks of bleeding and thrombotic events. Stopping both medications could lead to thrombotic events. Continuing both medications increases the bleeding risk.",
    "context": "|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nmonotherapy (Data Supplement 4). Based primarily on the CURE trial and PCI-CURE analyses, the prior recommendation that patients with NSTE-ACS treated with coronary stent implantation be treated with DAPT for at least 12 months is continued in this update and has been extrapolated to patients with",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery"
  }
]